US20210269431A1 - Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment - Google Patents
Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment Download PDFInfo
- Publication number
- US20210269431A1 US20210269431A1 US17/320,381 US202117320381A US2021269431A1 US 20210269431 A1 US20210269431 A1 US 20210269431A1 US 202117320381 A US202117320381 A US 202117320381A US 2021269431 A1 US2021269431 A1 US 2021269431A1
- Authority
- US
- United States
- Prior art keywords
- compound
- cancer
- prmt5
- formula
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101000924530 Homo sapiens Protein arginine N-methyltransferase 5 Proteins 0.000 title claims abstract description 138
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 title claims abstract description 138
- 238000000034 method Methods 0.000 title claims abstract description 46
- 238000011282 treatment Methods 0.000 title description 26
- 239000003112 inhibitor Substances 0.000 title description 16
- 150000003384 small molecules Chemical class 0.000 title description 6
- 101150097768 prmt5 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 240
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 83
- 230000000694 effects Effects 0.000 claims abstract description 77
- 201000011510 cancer Diseases 0.000 claims abstract description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- -1 —(CH2)nNR9R10 Chemical group 0.000 claims description 65
- 150000003839 salts Chemical class 0.000 claims description 49
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 206010009944 Colon cancer Diseases 0.000 claims description 36
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 36
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 34
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 33
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 32
- 108010057466 NF-kappa B Proteins 0.000 claims description 29
- 102000003945 NF-kappa B Human genes 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 25
- 125000001188 haloalkyl group Chemical group 0.000 claims description 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 18
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 16
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 15
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000003106 haloaryl group Chemical group 0.000 claims description 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 125000004104 aryloxy group Chemical group 0.000 claims description 12
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 12
- 125000004996 haloaryloxy group Chemical group 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 208000012902 Nervous system disease Diseases 0.000 claims description 11
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000002757 morpholinyl group Chemical group 0.000 claims description 9
- 125000004193 piperazinyl group Chemical group 0.000 claims description 9
- 125000005936 piperidyl group Chemical group 0.000 claims description 9
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000019838 Blood disease Diseases 0.000 claims description 7
- 208000014951 hematologic disease Diseases 0.000 claims description 7
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 208000030159 metabolic disease Diseases 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 230000006552 constitutive activation Effects 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 131
- 230000014509 gene expression Effects 0.000 description 45
- 125000004432 carbon atom Chemical group C* 0.000 description 44
- 125000005843 halogen group Chemical group 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 22
- 230000005764 inhibitory process Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000000134 MTT assay Methods 0.000 description 16
- 231100000002 MTT assay Toxicity 0.000 description 16
- 125000000842 isoxazolyl group Chemical group 0.000 description 16
- 125000003373 pyrazinyl group Chemical group 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 15
- 230000007423 decrease Effects 0.000 description 15
- 230000002018 overexpression Effects 0.000 description 15
- 239000011324 bead Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000003833 cell viability Effects 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000011987 methylation Effects 0.000 description 10
- 238000007069 methylation reaction Methods 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 101150042537 dld1 gene Proteins 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 208000015122 neurodegenerative disease Diseases 0.000 description 9
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000012815 AlphaLISA Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 208000025966 Neurological disease Diseases 0.000 description 8
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 125000002541 furyl group Chemical group 0.000 description 8
- 125000002632 imidazolidinyl group Chemical group 0.000 description 8
- 125000002883 imidazolyl group Chemical group 0.000 description 8
- 125000001786 isothiazolyl group Chemical group 0.000 description 8
- ZKXZLIFRWWKZRY-KRWDZBQOSA-N n-[(2s)-3-(3,4-dihydro-1h-isoquinolin-2-yl)-2-hydroxypropyl]-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide Chemical compound C([C@H](O)CN1CC2=CC=CC=C2CC1)NC(=O)C(N=CN=1)=CC=1NC1COC1 ZKXZLIFRWWKZRY-KRWDZBQOSA-N 0.000 description 8
- 125000001715 oxadiazolyl group Chemical group 0.000 description 8
- 125000002971 oxazolyl group Chemical group 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 125000003226 pyrazolyl group Chemical group 0.000 description 8
- 125000002098 pyridazinyl group Chemical group 0.000 description 8
- 125000004076 pyridyl group Chemical group 0.000 description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 description 8
- 125000001422 pyrrolinyl group Chemical group 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 125000003831 tetrazolyl group Chemical group 0.000 description 8
- 125000002769 thiazolinyl group Chemical group 0.000 description 8
- 125000000335 thiazolyl group Chemical group 0.000 description 8
- 125000001544 thienyl group Chemical group 0.000 description 8
- 125000004306 triazinyl group Chemical group 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 0 *[2*]C(=O)C(*)CC1CC2CCN1CC2CN1CCCCC1.B[1*]C1=C(C(B)C2=C([10*]B)C([9*]B)=C([8*]B)C([7*]B)=C2[6*]B)C([5*]B)=C([4*]B)C([3*]B)=C1[2*]B.CC.CC.CC.[1*]CC1=C2C([4*])=NN(C3=CC=CC=C3)C2=NC([2*])=N1.[5*]CC1=C2C([8*])=NN(C3=CC=CC=C3)C2=NC([6*])=N1 Chemical compound *[2*]C(=O)C(*)CC1CC2CCN1CC2CN1CCCCC1.B[1*]C1=C(C(B)C2=C([10*]B)C([9*]B)=C([8*]B)C([7*]B)=C2[6*]B)C([5*]B)=C([4*]B)C([3*]B)=C1[2*]B.CC.CC.CC.[1*]CC1=C2C([4*])=NN(C3=CC=CC=C3)C2=NC([2*])=N1.[5*]CC1=C2C([8*])=NN(C3=CC=CC=C3)C2=NC([6*])=N1 0.000 description 6
- 108090001007 Interleukin-8 Proteins 0.000 description 6
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000012292 cell migration Effects 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229960001252 methamphetamine Drugs 0.000 description 6
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 6
- 230000000926 neurological effect Effects 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- 229940125897 PRMT5 inhibitor Drugs 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229960005419 nitrogen Drugs 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 4
- 108091058560 IL8 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 3
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- UPAZOMJFUXPAJI-UHFFFAOYSA-N CC1=C(C)C=C(NC2=C3C=NN(C4=CC=CC=C4)C3=NC(NCCN(C)C)=N2)C=C1 Chemical compound CC1=C(C)C=C(NC2=C3C=NN(C4=CC=CC=C4)C3=NC(NCCN(C)C)=N2)C=C1 UPAZOMJFUXPAJI-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000282376 Panthera tigris Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003708 Protein arginine N-methyltransferase Human genes 0.000 description 2
- 108020000912 Protein arginine N-methyltransferase Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 108010026951 Short-Acting Insulin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002707 bendamustine Drugs 0.000 description 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 229960002802 bromocriptine Drugs 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 230000008777 canonical pathway Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 229960004270 nabumetone Drugs 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 229940090008 naprosyn Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- 239000008180 pharmaceutical surfactant Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 150000003873 salicylate salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 125000006168 tricyclic group Chemical group 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000012447 xenograft mouse model Methods 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AGNZJGPYNFNEJW-UHFFFAOYSA-N 4,6-dichloro-1-(4-chlorophenyl)pyrazolo[3,4-d]pyrimidine Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(Cl)=NC(Cl)=C2C=N1 AGNZJGPYNFNEJW-UHFFFAOYSA-N 0.000 description 1
- NAYSBOBKJMEREY-UHFFFAOYSA-N 4,6-dichloro-1-(4-methylphenyl)pyrazolo[3,4-d]pyrimidine Chemical compound C1=CC(C)=CC=C1N1C2=NC(Cl)=NC(Cl)=C2C=N1 NAYSBOBKJMEREY-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 238000007809 Boyden Chamber assay Methods 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- ZUTNWBAALFVPRU-UHFFFAOYSA-N CC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3Cl)C=C1.ClC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3Cl)C=C1.ClC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3N2CCOCC2)C=C1 Chemical compound CC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3Cl)C=C1.ClC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3Cl)C=C1.ClC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3N2CCOCC2)C=C1 ZUTNWBAALFVPRU-UHFFFAOYSA-N 0.000 description 1
- ASOWQVCOIAWBFZ-UHFFFAOYSA-N CC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3NCC2=CN=CC=C2)C=C1.ClC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3NCCN2CCCC2)C=C1.ClC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3NCCN2CCOCC2)C=C1 Chemical compound CC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3NCC2=CN=CC=C2)C=C1.ClC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3NCCN2CCCC2)C=C1.ClC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3NCCN2CCOCC2)C=C1 ASOWQVCOIAWBFZ-UHFFFAOYSA-N 0.000 description 1
- JGXPRDVSWGDODG-UHFFFAOYSA-N COC1=CC(C)=C(OC2=CC(C)=CC(O)=C2O)C(O)=C1 Chemical compound COC1=CC(C)=C(OC2=CC(C)=CC(O)=C2O)C(O)=C1 JGXPRDVSWGDODG-UHFFFAOYSA-N 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KOBZXZIOTXUOSN-UHFFFAOYSA-N ClC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3NCC2CCCO2)C=C1 Chemical compound ClC1=CC=C(N2N=CC3=C2/N=C(Cl)\N=C/3NCC2CCCO2)C=C1 KOBZXZIOTXUOSN-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010090613 Human Regular Insulin Proteins 0.000 description 1
- 102000013266 Human Regular Insulin Human genes 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000001284 I-kappa-B kinase Human genes 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010073961 Insulin Aspart Proteins 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 229940122254 Intermediate acting insulin Drugs 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102000008125 NF-kappa B p52 Subunit Human genes 0.000 description 1
- 108010074852 NF-kappa B p52 Subunit Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- JCUXESDDPXPSPQ-IBGZPJMESA-N O=C(NC[C@H](O)CN1CCC2=C(C=CC=C2)C1)C1=CC(CC2COC2)=NC=N1 Chemical compound O=C(NC[C@H](O)CN1CCC2=C(C=CC=C2)C1)C1=CC(CC2COC2)=NC=N1 JCUXESDDPXPSPQ-IBGZPJMESA-N 0.000 description 1
- XUMIOPFRZHMENK-AYRHNUGRSA-N O=C(NC[C@H]1C[C@@H]2CC[N@@]1C[C@@H]2CN1CCC(CC2=CC=CC=C2)CC1)C1=CC=C2OCOC2=C1 Chemical compound O=C(NC[C@H]1C[C@@H]2CC[N@@]1C[C@@H]2CN1CCC(CC2=CC=CC=C2)CC1)C1=CC=C2OCOC2=C1 XUMIOPFRZHMENK-AYRHNUGRSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229940123452 Rapid-acting insulin Drugs 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229940123958 Short-acting insulin Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 229940127322 Sodium-Glucose Transporter 2 Inhibitors Drugs 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010058339 Splenitis Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
- 229960004047 acamprosate Drugs 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960002054 acenocoumarol Drugs 0.000 description 1
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000037831 acute erythroleukemic leukemia Diseases 0.000 description 1
- 208000037832 acute lymphoblastic B-cell leukemia Diseases 0.000 description 1
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940031675 advate Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 230000006217 arginine-methylation Effects 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229940092117 atgam Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- KMPWYEUPVWOPIM-LSOMNZGLSA-N cinchonine Chemical compound C1=CC=C2C([C@@H]([C@H]3N4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-LSOMNZGLSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 208000007784 diverticulitis Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229940075117 droxia Drugs 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 229960000622 edoxaban Drugs 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 granisetron Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 229940103471 humulin Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229940096120 hydrea Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 229940075628 hypomethylating agent Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960004717 insulin aspart Drugs 0.000 description 1
- 108010050259 insulin degludec Proteins 0.000 description 1
- 229960004225 insulin degludec Drugs 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 108700039926 insulin glulisine Proteins 0.000 description 1
- 229960000696 insulin glulisine Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 208000029790 metamphetamine dependence Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 229960000619 nebivolol Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000008779 noncanonical pathway Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940103453 novolin Drugs 0.000 description 1
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229960004923 phenprocoumon Drugs 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960004310 piribedil Drugs 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- 108700027806 rGLP-1 Proteins 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 description 1
- 229950002652 safinamide Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000007399 subcellular translocation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical group CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 229960004751 varenicline Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Definitions
- PTMs Posttranslational modifications
- lysine and arginine are one of the most critical PTMs seen in nature and is implicated in a number of cellular processes, such as DNA damage and repair, gene transcription and translation, and protein subcellular localization and translocation.
- Arginine methylation is carried out by a group of enzymes termed protein arginine methyltransferases.
- protein arginine methyltransferase 5 PRMT5
- PRMT5 protein arginine methyltransferase 5
- the expression of PRMT5 is upregulated in a variety of cancers (e.g., liver cancer, pancreatic cancer, breast cancer, prostate cancer, and lung cancer, as well as lymphoma and melanoma), neurodegenerative disorders, inflammatory diseases, metabolic disorders, cardiovascular diseases, autoimmune disorders, and blood disorders.
- PRMT5 is an activator of NF- ⁇ B via dimethylating arginine 30 of the p65 subunit of NF- ⁇ B.
- NF- ⁇ B is a critical eukaryotic transcription factor whose family consists of five members: RelA (p65), RelB, cRel, NF- ⁇ B1 (p50 and its precursor p105), and NF- ⁇ B2 (p52 and its precursor p100) (Ghosh et al., Annu Rev Immunol, 1998; 16: 225-260).
- NF- ⁇ B signaling can be classified into canonical and non-canonical pathways.
- the canonical pathway has been well established as a key contributor to development of both pancreatic ductal adenocarcinoma (PDAC) (Prabhu et al., Oncotarget, 2014; 5: 10969-10975; Liou et al., J Cell Biol, 2013; 202: 563-577) and colorectal cancer (CRC) (Agarwal et al., Oncogene, 2005; 24(6): 1021-31; Yu et al., Int J Colorectal Dis, 2004; 19: 18-22).
- PDAC pancreatic ductal adenocarcinoma
- CRC colorectal cancer
- I ⁇ B ⁇ inhibitor of ⁇ B sequesters the p65:p50 heterodimer in an inactive state in the cytoplasm.
- I ⁇ B kinase When a cell receives extracellular signals, such as stress or pro-inflammatory cytokines, I ⁇ B kinase phosphorylates I ⁇ B ⁇ , which leads to the degradation of I ⁇ B and release of the p65:p50 complex and the activation of NF- ⁇ B target genes (Gilmore, Oncogene, 2006; 25: 6680-6684).
- NF- ⁇ B target genes A number of these downstream NF- ⁇ B target genes have been implicated in a wide range of diseases including cancer, neurodegenerative disorders, inflammatory diseases, metabolic disorders, cardiovascular diseases, autoimmune disorders, and blood disorders.
- the invention provides compounds of formula (I), formula (II), formula (III), and formula (IV)
- the invention further provides a method of treating a cancer in a subject comprising administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof to the subject.
- Also provided is a method of inhibiting the activity of PRMT5 in a cell comprising administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof to the cell.
- the invention also provides a method of treating a disease associated with increased expression or activity of PRMT5 in a subject comprising administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof to the subject.
- FIG. 1 is a schematic illustration of the AlphaLISA technique for the identification of small-molecule PRMT5 inhibitors.
- Biotinylated substrate histone H4 is incubated with PRMT5 and methyl donor, S-adenosyl-1-methionine (SAM).
- SAM S-adenosyl-1-methionine
- PRMT5 symmetrically dimethylates the third arginine (R3) on biotin-H4 to form biotin-H4R3me2.
- R3 arginine
- Donor beads have a streptavidin tag and bind to biotin-H4. Interaction between the Acceptor and Donor beads emits a chemiluminescent signal, which is detected by an ENVISIONTM Reader (PerkinElmer, Waltham, Mass.).
- ENVISIONTM Reader PerkinElmer, Waltham, Mass.
- FIGS. 2A-D depict the experimental results of studies to determine the PRMT5 inhibitory activity of a compound of formula (II), a compound of formula (III), and a compound of formula (IV).
- FIG. 2A is a calculation of IC 50 of compound (IIa) using AlphaLISA, which was found to be ⁇ 7.5 ⁇ M.
- FIG. 2B is a calculation of IC 50 of compound (IIIa) using AlphaLISA, which was found to be ⁇ 1.5 ⁇ M.
- FIG. 2C is a calculation of IC 50 of compound (IVa) using AlphaLISA, which was found to be ⁇ 16.5 ⁇ M.
- 2D is a co-immunoprecipitation-Western blot, showing that treatment with 20 ⁇ M compound (IIa) for 24 hours inhibited the methylation of PRMT5 substrate, p65, in 293-WT-p65-Flag cell lines.
- Flag beads were used to pull down WT-p65-Flag and samples were then probed with anti-symmetric dimethyl arginine motif Ab (sdme-RG Ab) to detect dimethylation levels of the p65 subunit.
- FIGS. 3A-B depict the results of lead optimization studies to identify PRMT5 inhibitors.
- FIG. 3A is a table showing the calculation of IC 50 of compounds (Ia), (If), and (Ig) compared to the parent compound (IIa) in HT-29 colon cancer cells.
- FIG. 3B is a table showing the calculation of IC 50 of compounds (Ia), (Ib), (If), and (Ig) compared to the parent compound (IIa) in PANC1 pancreatic cancer cells.
- FIGS. 4A-D depict the experimental results of studies to determine the expression level of PRMT5 in multiple cancer types.
- FIG. 4A is a Western blot showing that PRMT5 protein expression is higher in PDAC cell lines, AsPC1, MiaPaCa2 and PANC1, as compared to a control pancreatic cell line, HPNE. ⁇ -actin was used as a loading control.
- FIG. 4B is immunohistochemical (IHC) staining demonstrating that PRMT5 protein expression is higher in PDAC tumor tissue as compared to the tissue from normal (i.e., non-cancerous) controls.
- FIG. 4A is a Western blot showing that PRMT5 protein expression is higher in PDAC cell lines, AsPC1, MiaPaCa2 and PANC1, as compared to a control pancreatic cell line, HPNE. ⁇ -actin was used as a loading control.
- FIG. 4B is immunohistochemical (IHC) staining demonstrating that PRMT5 protein expression is higher in P
- FIG. 4C is a Western blot showing that PRMT5 protein expression is higher in CRC cell lines, HT29, HCT116 and DLD1, as compared to a control colon cell line, FHC. ⁇ -Actin was used as a loading control.
- FIG. 4D is IHC staining showing that PRMT5 protein expression was higher in the polyp stage and advanced stages of CRC, including stages II, III, IV, and the metastatic stage, compared to normal, non-cancerous colon tissue.
- FIGS. 5A-G depict the experimental results of studies to determine the effect of increased PRMT5 activity in cells.
- FIG. 5A is Western blot, confirming stable PRMT5 overexpression and shPRMT5 knockdown in PANC1 (left panel) and HT29 (right panel) cell lines. ⁇ -Actin was used as a loading control.
- FIGS. 5B and 5C are a cell proliferation assay, showing the effect of PRMT5 overexpression and shPRMT5 knockdown on cell growth in PANC1 ( FIG. 5B ) and HT29 ( FIG. 5C ) cell lines. Cell proliferation was significantly higher in the WT-PRMT5 cell lines, while shPRMT5 cells showed the opposite effect in both PANC1 and HT29 cell lines.
- FIGS. 5A is Western blot, confirming stable PRMT5 overexpression and shPRMT5 knockdown in PANC1 (left panel) and HT29 (right panel) cell lines. ⁇ -Actin was used as a loading control.
- FIGS. 5D and 5E are an anchorage-independent assay, showing the effect of PRMT5 overexpression and shPRMT5 knockdown on the colony size and colony number in PANC1 ( FIG. 5D ) and HT29 ( FIG. 5E ) cells. Anchorage-independent growth was significantly higher in the WT-PRMT5 cell lines, while significantly reduced in the shPRMT5 cells.
- FIGS. 5F and 5G are a cell migration assay, showing the effect of PRMT5 overexpression and shPRMT5 knockdown on cell migration in PANC1 ( FIG. 5F ) and HT29 ( FIG. 5G ) cell lines.
- the upper panels show representative pictures of the respective wells with 20 ⁇ magnification.
- the lower panel denotes the quantification for the change in migration between the cell lines. Cell migration was significantly higher in the WT-PRMT5 overexpression cells, while significantly reduced in the shPRMT5 cells.
- the data represent the means ⁇ SD for three independent experiments. *P ⁇ 0.05 vs. Ctr
- FIGS. 6A-C depict the results of experiments to determine the inhibitory effect of compound (Ia) in multiple cancer types.
- FIG. 6A is an MTT assay in PDAC cells (PANC1), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (Ia).
- FIG. 6B is an MTT assay in CRC cells (HT29), showing that cell viability decreased significantly in the presence of increased concentrations of compound (Ia).
- FIG. 6C is a table, summarizing the IC 50 values for compound (Ia) in PDAC and CRC cells, respectively.
- FIGS. 7A-D depict the results of experiments to determine the in vivo effect of compound (Ia).
- FIGS. 7A and 7B show that no significant changes in body weight were observed over the course of treatment in either PANC1 ( FIG. 7A ) or HT29 ( FIG. 7B ) model after treatment with 20 mg/kg of compound (Ia).
- FIGS. 8A-H depict the results of experiments to determine the inhibitory effect of compound (IIa) in multiple cancer types.
- FIGS. 8A-C are an MTT assay in PDAC cells (PANC1, MiaPaCa2, and AsPC1), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (IIa).
- FIGS. 8D-F are an MTT assay in CRC cells (HT29, HCT116, and DLD1), showing that cell viability decreased significantly in the presence of increased concentrations of compound (IIa).
- FIG. 8G is a table, summarizing the IC 50 values for compound (IIa) in PDAC and CRC cells, respectively.
- FIG. 8H is an anchorage-independent assay, showing that with increasing concentrations of compound (IIa), there was a significant decrease in the anchorage-independent growth ability in both PANC1 as well as HT29 cells.
- FIGS. 9A-G depict the results of experiments to determine the inhibitory effect of a commercially available PRMT5 inhibitor.
- FIGS. 9A-C are an MTT assay, showing that the commercially available PRMT5 inhibitor, EPZ015666, has lower efficacy to decrease cell viability in PDAC cells (PANC1, MiaPaCa2 and AsPC1) than that of compound (IIa).
- FIGS. 9D-F are an MTT assay, showing that EPZ015666 has lower efficacy to decrease cell viability in CRC cells (HT29, HCT116, and DLD1) than that of compound (IIa).
- the data represent the means ⁇ SD for three independent experiments. *P ⁇ 0.05 vs. Ctrl group.
- FIG. 9G is a table summarizing the IC 50 values for EPZ015666 in PDAC and CRC cell lines, respectively.
- FIGS. 10A-D depict the results of experiments to determine the in vivo effect of compound (IIa).
- FIGS. 10A and 10B show that no significant changes in body weight were observed over the course of treatment in either PANC1 ( FIG. 10A ) or HT29 ( FIG. 10B ) model after treatment with 20 mg/kg of compound (IIa).
- FIGS. 11A-L depicts the results of experiments to determine the effect of compound (IIa) on PRMT5 induced NF- ⁇ B activation.
- FIGS. 11A and 11B are a NF- ⁇ B luciferase assay, showing that overexpression of WT-PRMT5 led to NF- ⁇ B activation, while shPRMT5 resulted in the opposite effect in both PANC1 ( FIG. 11A ) and HT29 cells ( FIG. 11B ).
- FIGS. 11C and 11D are a luciferase assay, showing a decrease in NF- ⁇ B activation with increasing concentrations of compound (IIa) in PANC1 ( FIG. 11C ) and HT29 cells ( FIG. 11D ), respectively.
- EPZ015666 needed a higher concentration in order to reach a similar level of NF- ⁇ B inhibition as that of compound (IIa).
- the data represent the means ⁇ SD for three independent experiments. *P ⁇ 0.05 vs. Ctrl group.
- FIGS. 11E-H is a qPCR analysis, showing that overexpression of PRMT5 significantly enhanced IL-1 ⁇ -triggered typical NF- ⁇ B target genes expression, TNF ⁇ and IL8, while shPRMT5 exhibited the opposite effect, in both PANC1 ( FIGS. 11E and 11F ) and HT29 cells ( FIGS. 11G and 11H ).
- the data represent the means ⁇ SD for three independent experiments. *P ⁇ 0.05 vs. Ctrl group; #P ⁇ 0.05 vs.
- FIGS. 11I-L are a qPCR analysis, showing that treatment with compound (IIa) dramatically decreased NF- ⁇ B target genes (TNF ⁇ and IL8) expression, in both PANC1 ( FIGS. 11I and 11J ) and HT29 cells ( FIGS. 11K and 11L ).
- the data represent the means ⁇ SD for three independent experiments. *P ⁇ 0.5 vs. Ctrl group.
- FIGS. 12A-M depict the results of experiments to determine the inhibitory effect of compound (IIIa) and compound (IVa) in multiple cancer types.
- FIGS. 12A-12C are MTT assays in PDAC cells (PANC1 ( FIG. 12A ), MiaPaCa2 ( FIG. 12B ), and AsPC1 ( FIG. 12C )), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (IIIa).
- FIGS. 12D-12F are MTT assays in CRC cells (HT29 ( FIG. 12D ), HTC116 ( FIG. 12E ), and DLD1 ( FIG. 12F )), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (IIIa).
- FIGS. 12A-12C are MTT assays in PDAC cells (PANC1 ( FIG. 12A ), MiaPaCa2 ( FIG. 12B ), and AsPC1 ( FIG. 12C )
- FIGS. 12D-12F are MTT assays in
- FIGS. 12J-12L are MTT assays in PDAC cells (PANC1 ( FIG. 12G ), MiaPaCa2 ( FIG. 12H ), and AsPC1 ( FIG. 12I )), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (IVa).
- FIGS. 12J-12L are MTT assays in CRC cells (HT29 ( FIG. 12J ), HTC116 ( FIG. 12K ), and DLD1 ( FIG. 12L )), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (IVa).
- FIG. 12M is a table, summarizing the IC 50 values for compound (IIIa) and compound (IVa) in PDAC and CRC cells, respectively.
- FIGS. 13A-B depict the results of experiments to identify the expression of PRMT5 in neurodegenerative disorders.
- FIG. 13A is a Western blot showing the expression of PRMT5 in cell lysate with PRMT5 overexpression (lane 2), non-transgenic B6 mice (6M) (lanes 3-5), hTau (humanized tau mice) (3M) (lanes 6-7), hTau (6M) (lanes 8-9), htau;Trem2 ⁇ / ⁇ mice (6M) (lanes 10-11), hTau (18M) (lanes 12-13), and APPPS1 amyloid mice (lanes 14-15).
- FIG. 13B is a graph depicting the Western blot data of PRMT5 expression. *P ⁇ 0.5 vs. Ctrl group.
- FIGS. 14A-B depicts the results of experiments to show the effect of compound (IIa) in neurological disorders.
- FIG. 15 is a graph showing the expression level of PRMT5 in multiple human tissues, including heart tissue, as determined using the TiGER database.
- the present invention is directed to compounds of formulas (I)-(IV) that have been discovered to be effective in inhibiting PRMT5, which enables the effective use of the compounds in treating various diseases associated with an increased expression or activity of PRMT5.
- R 1 is hydrogen, halo, C 1 -C 8 alkyl, C 3 -C 6 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- R 2 is C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, C 1 -C 8 alkoxy, C 3 -C 6 cycloalkyloxy, aryloxy, halo, C 1 -C 8 haloalkoxy, C 1 -C 8 haloalkyl, haloaryl, haloaryloxy, —CN, —NO 2 , —(CH 2 ) n C(O)R 5 , —(CH 2 ) n CO 2 R 5 , —(CH 2 ) n C(O)NR 5 R 6 , —(CH 2 ) n NR 5 C(O)R 6 , or —(CH 2 ) n NR 5 R 6 ;
- R 3 is hydroxy, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkylalkyl, C 1 -C 8 alkoxy, C 3 -C 6 cycloalkyloxy, heterocycloalkyl, aryl, arylalkyl, heteroaryl, aryloxy, halo, C 1 -C 8 haloalkyl, C 1 -C 8 haloalkoxy, haloaryl, haloaryloxy, —CN, —NO 2 , —C(O)R 5 , —CO 2 R 5 , —C(O)NR 5 R 6 , —NR 5 C(O)R 6 , —(CH 2 ) n NR 5 R 6 , —(CH 2 ) n SO 2 NR 5 R 6 , —(CH 2 ) n SO 2 R 5 , aryl
- R 4 is H, hydroxy, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 6 cycloalkyl, C 1 -C 8 haloalkyl, —CN, —NO 2 , —(CH 2 ) n NR 5 R 6 , heterocycloalkyl, aryl, or heteroaryl;
- X is a bond, —(CH 2 ) o CR 5 R 6 —, —CR 5 R 6 (CH 2 ) o —, —(CH 2 ) o NR 5 —, —NR 5 (CH 2 ) o —, —(CH 2 ) o O—, or —O(CH 2 ) o —,
- R 5 and R 6 are the same or different and each is H or C 1 -C 8 alkyl
- n, and o are the same or different and each is 0 or an integer from 1-5, or
- R 1 is hydrogen, halo, C 1 -C 8 alkyl, C 3 -C 6 cycloalkyl, aryl, heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl,
- R 1 is halo, heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl.
- heteroaryl selected from the group consisting of pyri
- R 2 is halo, C 1 -C 8 haloalkoxy, C 1 -C 8 haloalkyl, haloaryl, or haloaryloxy.
- R 3 is C 1 -C 8 alkyl, halo, or C 1 -C 8 haloalkyl.
- R 4 is H.
- X is a bond, —(CH 2 ) o NR 5 —, or —NR 5 (CH 2 ) o —.
- X is a bond or —NH(CH 2 ) o — (e.g., —NH(CH 2 )— or —NH(CH 2 ) 2 —).
- m is 1.
- n 0, 1, or 2.
- o is 1 or 2.
- R 5 and R 6 are each H.
- R 1 is heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl.
- R′ is halo, heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl; R 2 is halo, heterocycloalkyl selected from
- R 1 is heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl;
- R 2 is halo;
- R 3 is C 1
- the compound of formula (I) is in the form of a pharmaceutically acceptable salt.
- Exemplary compounds of formula (I) include compounds (Ia), (Ib), (Ic), (Id), (Ie), (If), and (Ig), are set forth below. Pharmaceutically acceptable salts of these exemplary compounds are also envisioned.
- the present invention also provides a compound of formula (II):
- R 5 is halo, heterocycloalkyl, or heteroaryl
- R 6 is C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, C 1 -C 8 alkoxy, C 3 -C 6 cycloalkyloxy, aryloxy, halo, C 1 -C 8 haloalkoxy, C 1 -C 8 haloalkyl, haloaryl,
- haloaryloxy —CN, —NO 2 , —(CH 2 ) n C(O)R 9 , —(CH 2 ) n CO 2 R 9 , —(CH 2 ) n C(O)NR 9 R 10 , —(CH 2 ) n NR 9 C(O)R 10 , —(CH 2 ) n NR 9 R 10 , —NR 11 (CH 2 ) n NR 9 R 10 ; or
- R 7 is hydroxy, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkylalkyl, C 1 -C 8 alkoxy, C 3 -C 6 cycloalkyloxy, heterocycloalkyl, aryl, arylalkyl, heteroaryl, aryloxy, halo, C 1 -C 8 haloalkyl, C 1 -C 8 haloalkoxy, haloaryl,
- haloaryloxy —CN, —NO 2 , —C(O)R 9 , —CO 2 R 9 , —C(O)NR 9 R 10 , —NR 9 C(O)R 10 , —(CH 2 ) n NR 9 R 10 , —(CH 2 ) n SO 2 NR 9 R 10 , —(CH 2 ) n SO 2 R 9 , aryl; or
- R 8 is H, hydroxy, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 6 cycloalkyl, C 1 -C 8 haloalkyl, —CN, —NO 2 , —(CH 2 ) n NR 9 R 10 , heterocycloalkyl, aryl, or heteroaryl;
- X is a bond, —(CH 2 ) o CR 9 R 10 —, —CR 9 R 10 (CH 2 ) o —, —(CH 2 ) o NR 9 —, —NR 9 (CH 2 ) o —, —(CH 2 ) o O—, or —O(CH 2 ) o —,
- R 9 , R 10 , and R 11 are the same or different and each is H or C 1 -C 8 alkyl;
- n, and o are the same or different and each is 0 or an integer from 1-5, or
- R 1 is hydrogen, halo, C 1 -C 8 alkyl, C 3 -C 6 cycloalkyl, aryl, heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazo
- R 1 is halo, heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl.
- heteroaryl selected from the group consisting of pyri
- R 1 is substituted phenyl, as described herein, including phenyl substituted with C 1 -C 8 alkyl, halo, or hydroxy.
- R 1 is 3,4-di-C 1 -C 8 alkylphenyl (e.g., 3,4-dimethylphenyl).
- R 2 is halo, C 1 -C 8 haloalkoxy, C 1 -C 8 haloalkyl, haloaryl, or haloaryloxy.
- R 2 is —NR 7 (CH 2 ) n NR 5 R 6 .
- R 5 and R 6 are both C 1 -C 8 alkyl, R 7 is H, and/or n is 1 or 2.
- R 2 is —NR 7 (CH 2 ) n NR 5 R 6 ; R 5 and R 6 are methyl; R 7 is H; and n is 2.
- R 3 is C 1 -C 8 alkyl, halo, or C 1 -C 8 haloalkyl.
- R 4 is H.
- X is a bond, —(CH 2 ) o NR 5 —, or —NR 5 (CH 2 ) o —.
- X is a bond or —NH(CH 2 ) o — (e.g., —NH—, —NH(CH 2 )— or —NH(CH 2 ) 2 —).
- m is 0 or 1. In some preferred embodiments, m is 0, and the phenyl ring does not include any substituents.
- n 0, 1, or 2.
- o is 0, 1, or 2.
- R 5 and R 6 are each H.
- An exemplary compound of formula (II) is compound (IIa). Pharmaceutically acceptable salts of the exemplary compound are also envisioned.
- IV preferably is not chloro.
- the compound of formula (I) or (II) is not 4,6-dichloro-1-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidine or 4,6-dichloro-1-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidine.
- the present invention also provides a compound of formula (III):
- R 1A and R 2A are the same or different and each is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, hydroxy, C 1 -C 8 alkoxy, C 3 -C 6 cycloalkyloxy, aryloxy, halo, C 1 -C 8 haloalkoxy, C 1 -C 8
- X 1A is O, S, or —NR 11A ;
- R 11A and R 12A are the same or different and each is H or C 1 -C 8 alkyl
- n is an integer from 1-4;
- n is 0 or an integer from 1-5, or
- An exemplary compound of formula (III) is compound (IIIa). Pharmaceutically acceptable salts of the exemplary compound also are envisioned.
- the present invention further provides a compound of formula (IV):
- R 1B , R 2B , R 3B , R 4B , R 5B , R 6B , R 7B , R 8B , R 9B , and R 10B are the same or different and each is hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, hydroxy, C 1 -C 8 alkoxy, C 3 -C 6 cycloalkyloxy, aryloxy, halo, C 1 -C 8 haloalkoxy, C 1 -C 8 haloalkyl, haloaryl,
- haloaryloxy —CN, —NO 2 , —(CH 2 ) n C(O)R 11A , —(CH 2 ) n CO 2 R 11A , —(CH 2 ) n C(O)NR 11A R 12A , —(CH 2 ) n NR 11A C(O)R 12A , or —(CH 2 ) n NR 11A R 12A ; wherein each moiety other than hydrogen, hydroxy, halo, —CN, and —NO 2 is optionally substituted;
- X 1B is O, S, or —NR 11B ;
- R 11B and R 12B are the same or different and each is H or C 1 -C 8 alkyl, or
- An exemplary compound of formula (IV) is compound (IVa). Pharmaceutically acceptable salts of the exemplary compound are also envisioned.
- alkyl implies a straight-chain or branched alkyl substituent containing from, for example, from about 1 to about 8 carbon atoms, e.g., from about 1 to about 6 carbon atoms.
- alkyl group include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, and the like.
- alkyl occurs as part of a group, such as, e.g., in C 3 -C 6 cycloalkylalkyl, hydroxyalkyl, haloalkyl (e.g., monohaloalkyl, dihaloalkyl, and trihaloalkyl), cyanoalkyl, aminoalkyl, alkylamino, dialkylamino, arylalkyl, etc.
- the alkyl can be substituted or unsubstituted, as described herein. Even in instances in which the alkyl is an alkylene chain (e.g., —(CH 2 ) n —), the alkyl group can be substituted or unsubstituted.
- An example of a substituted alkylene chain includes —CF 2 -cyclopropyl.
- alkenyl means a linear alkenyl substituent containing from, for example, about 2 to about 8 carbon atoms (branched alkenyls are about 3 to about 8 carbons atoms), e.g., from about 3 to about 6 carbon atoms (branched alkenyls are about 3 to about 6 carbons atoms).
- the alkenyl group is a C 2 -C 4 alkenyl.
- alkenyl group examples include ethenyl, allyl, 2-propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1-hexenyl, and the like.
- the alkenyl can be substituted or unsubstituted, as described herein.
- cycloalkyl means a cyclic alkyl moiety containing from, for example, 3 to 6 carbon atoms or from 5 to 6 carbon atoms. Examples of such moieties include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- the cycloalkyl can be substituted or unsubstituted, as described herein.
- a substituted cycloalkyl includes a halo- or haloalkyl-substituted cyclopropyl, such as 2-fluorocyclopropyl, 2,2-difluorocyclopropyl, 1-(trifluoromethyl)cyclopropyl, and 2-(trifluoromethyl)cyclopropyl.
- hydroxy refers to the group —OH.
- alkoxy and cycloalkyloxy embrace linear or branched alkyl and cycloalkyl groups, respectively, that are attached to a divalent oxygen.
- the alkyl and cycloalkyl groups are the same as described herein.
- aryloxy refers to substituents that have an aryl group attached to divalent oxygen.
- the aryl group is the same as described herein.
- halo refers to a halogen selected from fluorine, chlorine, bromine, and iodine.
- aryl refers to a mono, bi, or tricyclic carbocyclic ring system having one, two, or three aromatic rings, for example, phenyl, naphthyl, anthracenyl, or biphenyl.
- aryl refers to an unsubstituted or substituted aromatic carbocyclic moiety, as commonly understood in the art, and includes monocyclic and polycyclic aromatics such as, for example, phenyl, biphenyl, naphthyl, anthracenyl, pyrenyl, and the like.
- heteroaryl refers to aromatic 5 or 6 membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S, or N) in at least one of the rings.
- Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom.
- the fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated.
- the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen atoms may optionally be quaternized.
- Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic.
- the heteroaryl group may be attached at any available nitrogen or carbon atom of any ring.
- heteroaryl groups are pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)- and (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl.
- the heteroaryl can be substituted or unsubstituted, as described herein.
- heterocycloalkyl means a stable, saturated, or partially unsaturated monocyclic, bicyclic, and spiro ring system containing 3 to 7 ring members of carbon atoms and other atoms selected from nitrogen, sulfur, and/or oxygen.
- a heterocycloalkyl is a 5, 6, or 7-membered monocyclic ring and contains one, two, or three heteroatoms selected from nitrogen, oxygen, and sulfur.
- the heterocycloalkyl may be attached to the parent structure through a carbon atom or through any heteroatom of the heterocycloalkyl that results in a stable structure.
- heterocycloalkyl rings examples include isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl.
- the heterocycloalkyl can be substituted or unsubstituted, as described herein.
- the alkyl, alkoxy, and alkylamino groups can be linear or branched.
- any substituent that is not hydrogen e.g., C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or heterocycloalkyl
- the substituted moiety typically comprises at least one substituent (e.g., 1, 2, 3, 4, 5, 6, etc.) in any suitable position (e.g., 1-, 2-, 3-, 4-, 5-, or 6-position, etc.).
- aryl group When an aryl group is substituted with a substituent, e.g., halo, amino, alkyl, OH, alkoxy, and others, the aromatic ring hydrogen is replaced with the substituent and this can take place in any of the available hydrogens, e.g., 2, 3, 4, 5, and/or 6-position wherein the 1-position is the point of attachment of the aryl group in the compound of the present invention.
- a substituent e.g., halo, amino, alkyl, OH, alkoxy, and others
- Suitable substituents include, e.g., halo, alkyl, alkenyl, alkynyl, hydroxy, nitro, cyano, amino, alkylamino, alkoxy, aryloxy, aralkoxy, carboxyl, carboxyalkyl, carboxyalkyloxy, amido, alkylamido, haloalkylamido, aryl, heteroaryl, and heterocycloalkyl, each of which is described herein.
- the substituent is at least one alkyl, halo, and/or haloalkyl (e.g., 1 or 2).
- a range of the number of atoms in a structure is indicated (e.g., a C 1-12 , C 1-8 , C 1-6 , or C 1-4 alkyl, cycloalkyl, etc.), it is specifically contemplated that any sub-range or individual number of carbon atoms falling within the indicated range also can be used.
- any chemical group e.g., alkyl, cycloalkyl, etc.
- any chemical group e.g., alkyl, cycloalkyl, etc.
- any sub-range thereof e.g., 1-2 carbon atoms, 1-3 carbon atoms, 1-4 carbon atoms, 1-5 carbon atoms, 1-6 carbon atoms, 1-7 carbon atoms, 1-8 carbon atoms, 2-3 carbon atoms, 2-4 carbon atoms, 2-5 carbon atoms,
- the subscript “m” represent the number of substituents of R 3 , in which each substituent of R 3 , can be the same or different.
- the subscripts m can be either 0 or an integer from 1-5 (i.e., 1, 2, 3, 4, or 5). When m is 0, then the R 3 is not present in the compound of formula (I) or (II).
- the subscripts “n” and “o” represent the number of methylene repeat units.
- the subscripts n and o are either 0 or an integer from 1-5 (i.e., 1, 2, 3, 4, or 5). When n or o is 0, then the respective moiety does not contain any methylene repeat units.
- salts or “pharmaceutically acceptable salt” is intended to include nontoxic salts synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
- an inorganic acid e.g., hydrochloric acid, sulfuric acid, phosphoric acid, or hydrobromic acid
- an organic acid e.g., oxalic acid, malonic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, or benzylsulfonic acid
- an inorganic base e.g., sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, or ammonium hydroxide
- an organic base e.g., methylamine, diethylamine, triethylamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, guanidine, choline, or cinchonine
- an amino acid e.g., lysine, arginine, or alanine
- nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typical.
- suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, Pa., 1990, p. 1445, and Journal of Pharmaceutical Science, 66, 2-19 (1977).
- they can be a salt of an alkali metal (e.g., sodium or potassium), alkaline earth metal (e.g., calcium), or ammonium.
- a pharmaceutical composition will comprise at least one compound of formulas (I)-(IV), or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable excipients described herein for example, vehicles, adjuvants, carriers or diluents, are well-known to those who are skilled in the art and are readily available to the public.
- the pharmaceutically acceptable carrier is one that is chemically inert to the active compounds and one that has no detrimental side effects or toxicity under the conditions of use.
- compositions can be administered as oral, sublingual, transdermal, subcutaneous, topical, absorption through epithelial or mucocutaneous linings, intravenous, intranasal, intraarterial, intramuscular, intratumoral, peritumoral, interperitoneal, intrathecal, rectal, vaginal, or aerosol formulations.
- the pharmaceutical composition is administered orally or intravenously.
- Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice and include an additive, such as cyclodextrin (e.g., ⁇ -, ⁇ -, or ⁇ -cyclodextrin, hydroxypropyl cyclodextrin) or polyethylene glycol (e.g., PEG400); (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions and gels.
- diluents such as water, saline, or orange juice
- an additive such as cyclodextrin (e.g., ⁇ -, ⁇ -, or ⁇ -cyclodextrin, hydroxypropyl cyclod
- Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
- diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
- Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and cornstarch.
- Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers.
- Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.
- a flavor usually sucrose and acacia or tragacanth
- pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.
- Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
- the compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, glycerol ketals, such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, such as poly(ethyleneglycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methyl
- Oils which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
- Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts
- suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylene-polypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-beta-aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (3) mixtures thereof.
- the parenteral formulations will typically contain from about 0.5 to about 25% by weight of the inhibitors in solution. Suitable preservatives and buffers can be used in such formulations. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations ranges from about 5 to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
- HLB hydrophile-lipophile balance
- parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use.
- sterile liquid carrier for example, water
- Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
- the inhibitors may be made into injectable formulations.
- the requirements for effective pharmaceutical carriers for injectable compositions are well known to those of ordinary skill in the art. See Pharmaceutics and Pharmacy Practice , J. B. Lippincott Co., Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs , Toissel, 4th ed., pages 622-630 (1986).
- Topically applied compositions are generally in the form of liquids (e.g., mouthwash), creams, pastes, lotions and gels.
- Topical administration includes application to the oral mucosa, which includes the oral cavity, oral epithelium, palate, gingival, and the nasal mucosa.
- the composition contains at least one active component and a suitable vehicle or carrier. It may also contain other components, such as an anti-irritant.
- the carrier can be a liquid, solid or semi-solid.
- the composition is an aqueous solution, such as a mouthwash.
- the composition can be a dispersion, emulsion, gel, lotion or cream vehicle for the various components.
- the primary vehicle is water or a biocompatible solvent that is substantially neutral or that has been rendered substantially neutral.
- the liquid vehicle can include other materials, such as buffers, alcohols, glycerin, and mineral oils with various emulsifiers or dispersing agents as known in the art to obtain the desired pH, consistency and viscosity. It is possible that the compositions can be produced as solids, such as powders or granules. The solids can be applied directly or dissolved in water or a biocompatible solvent prior to use to form a solution that is substantially neutral or that has been rendered substantially neutral and that can then be applied to the target site.
- the vehicle for topical application to the skin can include water, buffered solutions, various alcohols, glycols such as glycerin, lipid materials such as fatty acids, mineral oils, phosphoglycerides, collagen, gelatin and silicone based materials.
- the compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof, alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation.
- aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer
- the dose administered to the subject, particularly human and other mammals, in accordance with the present invention should be sufficient to affect the desired response.
- dosage will depend upon a variety of factors, including the age, condition or disease state, predisposition to disease, genetic defect or defects, and body weight of the mammal.
- the size of the dose will also be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular inhibitor and the desired effect. It will be appreciated by one of skill in the art that various conditions or disease states may require prolonged treatment involving multiple administrations.
- the inventive methods comprise administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof for the treatment of a disease.
- treatment refers to obtaining a desired pharmacologic and/or physiologic effect.
- the effect is therapeutic, i.e., the effect partially or completely cures a disease and/or adverse symptom attributable to the disease.
- a “pharmaceutically effective amount” means an amount sufficient to show a meaningful benefit in an individual, e.g., promoting at least one aspect of tumor cell cytotoxicity (e.g., inhibition of growth, inhibiting survival of a cancer cell, reducing proliferation, reducing size and/or mass of a tumor (e.g., solid tumor)), or treatment, healing, prevention, delay of onset, halting, or amelioration of other relevant medical condition(s) associated with a particular cancer.
- the meaningful benefit observed in the patient can be to any suitable degree (e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or 90% or more).
- one or more symptoms of the cancer are prevented, reduced, halted, or eliminated subsequent to administration of a compound of formula (I), formula (II), formula (III), or formula (IV), including compounds of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (IIa), (IIIa), and (IVa), or a pharmaceutically acceptable salt thereof, thereby effectively treating the cancer to at least some degree.
- Effective amounts can vary depending upon the biological effect desired in the individual, condition to be treated, and/or the specific characteristics of the compound of formula (I), formula (II), formula (III), or formula (IV), including compounds of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (IIa), (IIIa), and (IVa), or a pharmaceutically acceptable salt thereof, and the individual.
- any suitable dose of the compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof can be administered to the patient (e.g., human), according to the type of disease (e.g., cancer) to be treated.
- the dose of the compound of formula (I), formula (II), formula (III), or formula (IV), including compounds of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (IIa), (IIIa), and (IVa), or a pharmaceutically acceptable salt thereof desirably comprises about 0.1 mg per kilogram (kg) of the body weight of the mammal (mg/kg) to about 400 mg/kg (e.g., about 0.75 mg/kg, about 5 mg/kg, about 30 mg/kg, about 75 mg/kg, about 100 mg/kg, about 200 mg/kg, or about 300 mg/kg).
- the dose of the compound formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof comprises about 0.5 mg/kg to about 300 mg/kg (e.g., about 0.75 mg/kg, about 5 mg/kg, about 50 mg/kg, about 100 mg/kg, or about 200 mg/kg), about 10 mg/kg to about 200 mg/kg (e.g., about 25 mg/kg, about 75 mg/kg, or about 150 mg/kg), or about 50 mg/kg to about 100 mg/kg (e.g., about 60 mg/kg, about 70 mg/kg, or about 90 mg/kg).
- about 0.5 mg/kg to about 300 mg/kg e.g., about 0.75 mg/kg, about 5 mg/kg, about 50 mg/kg, about 100 mg/kg, or about 200 mg/kg
- about 10 mg/kg to about 200 mg/kg e.g., about 25 mg/kg, about 75 mg/kg, or about 150 mg/kg
- a compound of formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV), or a pharmaceutically acceptable salt thereof can inhibit the activity of PRMT5 in a cell. Elevated activity of PRMT5 has been described in the art for multiple disorders, including various types of cancer (Wei et al., Proc. Natl. Acad. Sci., 110(33): 13516-13521 (2013); Lu et al., Cancer Res., 75(18): 3692-3695 (2015)).
- the terms “elevated activity,” “increased activity” and the like refers to any increase in the enzymatic activity of the protein, any increase in the total amount of protein present, or any increase in the level of gene (e.g., mRNA, RNA, DNA) expression. Increased activity is measured against a control sample. For example, the mRNA level of PRMT5 is measured in a cancer cell and is compared to the PRMT5 mRNA level in a non-cancer control cell of the same tissue type.
- Methods to identify subjects or cells with increased activity of a protein, increased level of a protein, or increased expression of a gene are routine in the art and include, for example, Western blotting, RT-PCR, PCR, quantitative PCR, ELISA, and enzyme assays. Additionally, the methods described herein can also be used by a person of ordinary skill in the art to determine increased activity of a protein, increased level of a protein or increased expression of a gene.
- One aspect of the inventive method provides a method of treating cancer in a subject comprising administering a pharmaceutically effective amount of formula (I), formula (II), formula (III), or formula (IV), which includes the compounds of formulas (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (IIa), (IIIa), and (IVa), or a pharmaceutically acceptable salt thereof, to the subject whereby the cancer is treated.
- the term “subject” includes any living organism that would benefit from inhibition of PRMT5.
- the subject is a mammal.
- Mammals include, but are not limited to, the order Rodentia, such as mice, and the order Logomorpha, such as rabbits.
- the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs), Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses).
- the mammals are of the order Primates, Ceboids, or Simioids (monkeys) or of the order Anthropoids (humans and apes).
- the subject is a human.
- the type of cancer is not particularly limited.
- the cancer is characterized as a cancer that has increased activity of PRMT5 compared to a non-cancer sample of the same tissue type.
- the identification of a cancer that has increased activity of PRMT5 can be readily identified by a person of ordinary skill in the art using routine methods (e.g., Western blot, enzyme-linked immunosorbent assay (ELISA), or polymerase chain reaction (PCR)), including the methods described herein.
- the cancer is characterized as a cancer that has increased activity of NF- ⁇ B compared to a non-cancer sample of the same tissue type.
- a cancer that has increased activity of NF- ⁇ B can be readily identified by a person of ordinary skill in the art using routine methods (e.g., Western blot, ELISA, or PCR).
- the cancer has increased activity of PRMT5 and increased activity of NF- ⁇ B.
- cancers treatable with the inventive method include cancers of the head and neck, eye, skin, mouth, throat, esophagus, chest, bone, lung, colon, sigmoid, rectum, stomach, prostate, breast, ovaries, kidney, liver, pancreas, brain, intestine, heart, or adrenals.
- cancers include solid tumor, sarcoma, carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendothelio sarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma,
- the cancer is a solid tumor.
- the cancer is selected from gastrointestinal cancer, skin cancer, lung cancer, brain cancer, ovarian cancer, prostate cancer, lymphoma, melanoma, and breast cancer.
- the cancer is pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, pancreatic cancer, or liver cancer.
- Another aspect of the inventive method provides a method of inhibiting the activity of PRMT5 in a cell, comprising administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof to the cell, whereby the activity of PRMT5 is inhibited.
- Inhibition of PRMT5 includes any decrease in methyltransferase activity compared to an untreated or control treated subject.
- Inhibition or PRMT5 also includes any decrease in the protein level of PRMT5 in a subject compared to an untreated or control treated subject. Inhibition of PRMT5 can be demonstrated, for example, by a decrease in NF- ⁇ B activity.
- the cell is treated in vitro or ex vivo. In other embodiments the cell is in a subject.
- the type of cell in which PRMT5 is inhibited is not particularly limited.
- the cell is a cancer cell.
- the cancer cell can be from any cancer type described in the foregoing.
- the cancer cell is from PDAC, colorectal cancer, pancreatic cancer, or liver cancer.
- PRMT5 activity has been shown to be increased in a variety of disease, and inhibition of PRMT5 has been described in the art as a viable treatment of multiple diseases, including autoimmune diseases, inflammatory disease, metabolic disorders, neurological and neurodegenerative disorders, cardiovascular diseases, and blood disorders (Kim et al., Mediators Inflamm., 2016; Published online doi: 10.1155/2017/4028353; Stopa et al., Cell Mol.
- another aspect of the invention provides a method of treating a disease associated with increased expression of PRMT5 in a subject, comprising administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof to the subject, thereby treating the disease.
- Suitable diseases that can be treated include, for example, autoimmune diseases, inflammatory disease, metabolic disorders, neurological and neurodegenerative disorders, cardiovascular diseases, and blood disorders.
- autoimmune diseases treatable with the inventive method include alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, dermatomyositis, diabetes (type 1), juvenile idiopathic arthritis, glomerulonephritis, Graves' disease, Guillain-Barré syndrome, idiopathic thrombocytopenic purpura, myasthenia gravis, myocarditis, multiple sclerosis, pemphigus/pemphigoid, pernicious anemia, polyarteritis nodosa, polymyositis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, scleroderma/systemic sclerosis, Sjögren's syndrome, systemic lupus erythematosus, thyroiditis, uveitis, vitiligo, and granulomatosis with polyangiitis (Wegener's).
- inflammatory diseases treatable with the inventive method include ankylosing spondylitis, arthritis (e.g., osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis), gout, eczema, gastritis, splenitis, sinusitis, hepatitis, nephritis, psoriasis, vasculitis, atherosclerosis, sarcoidosis, pleurisy, asthma, atherosclerosis, Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), systemic lupus erythematous (SLE), nephritis, and ulcerative colitis.
- arthritis e.g., osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis
- gout eczema
- gastritis sple
- Examples of metabolic disorders treatable with the inventive method include diabetes (type 1 and type 2), phenylketonuira, and obesity.
- Examples of neurological and neurodegenerative disorders treatable with the inventive method include drug abuse (e.g., methamphetamine addiction), Alzheimer's disease, amyotrophic lateral sclerosis, Angelman syndrome, Asperger syndrome, autism, bipolar disorder, cerebral arteriosclerosis, Charcot-Marie-Tooth disease, chronic pain, Cushing's syndrome, Creutzfeldt-Jakob disease, dementia, Huntington's disease, inclusion body myositis, Parkinson's disease, and Reye syndrome.
- drug abuse e.g., methamphetamine addiction
- Alzheimer's disease amyotrophic lateral sclerosis
- Angelman syndrome Asperger syndrome
- autism bipolar disorder
- cerebral arteriosclerosis Charcot-Marie-Tooth disease
- chronic pain Cushing's syndrome
- Creutzfeldt-Jakob disease dementia
- Huntington's disease inclusion body myositis
- Parkinson's disease Parkinson's disease
- Reye syndrome e.g., Reye syndrome
- cardiovascular disorders treatable with the inventive method include coronary artery disease, angina, myocardial infarction, stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.
- blood disorders treatable with the inventive method include anemia, bleeding disorders, hemophilia, sickle cell anemia, hemoglobinopathy, ⁇ -thalassemia, and blood clots.
- a compound formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV), or a pharmaceutically acceptable salt thereof can be co-administered with an anti-cancer agent (e.g., a chemotherapeutic agent) and/or radiation therapy.
- the method comprises administering an amount of a compound or salt that is effective to sensitize the cancer cells to one or more therapeutic regimens (e.g., chemotherapy or radiation therapy).
- therapeutic regimens e.g., chemotherapy or radiation therapy.
- One or more than one, e.g., two, three, or more anti-cancer agents can be administered.
- the present invention is directed a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination of a compound of formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV), or a pharmaceutically acceptable salt thereof and at least one anti-cancer agent (e.g., chemotherapeutic agent).
- anti-cancer agents include platinum compounds (e.g., cisplatin, carboplatin, oxaliplatin), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, nitrogen mustard, thiotepa, melphalan, busulfan, procarbazine, streptozocin, temozolomide, dacarbazine, bendamustine), antitumor antibiotics (e.g., daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, bleomycin, mytomycin C, plicamycin, dactinomycin), taxanes (e.g., paclitaxel and docetaxel), antimetabolites (e.g., 5-fluorouracil, cytarabine, premetrexed, thioguanine, floxuridine, capecitabine, and methotrex
- a compound formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV), or a pharmaceutically acceptable salt thereof can be co-administered with an agent that treats a disease associated with increased activity of PRMT5.
- One or more than one, e.g., two, three, or more agents can be administered.
- the present invention is directed a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination of a compound of formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV), or a pharmaceutically acceptable salt thereof and at least one other PRMT5 disease modifying agent.
- autoimmune disease and inflammatory disease treating agents include alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, nitrogen mustard, thiotepa, melphalan, busulfan, procarbazine, streptozocin, temozolomide, dacarbazine, bendamustine), antimetabolites (e.g., methotrexate, azathioprine, mercaptopurine, flurouracil), cytotoxic antibiotics (e.g., daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, bleomycin, mytomycin C, plicamycin, dactinomycin), polyclonal antibodies (e.g., atgam, thymoglobuline), monoclonal antibodies (e.g., muromonab-CD3, basiliximab, daclizumab, omalizuma
- metabolic disorder treating agents include short-acting insulin (e.g., humulin, novolin), rapid-acting insulin (e.g., insulin aspart, insulin glulisine, insulin lispro), intermediate acting insulin (e.g., insulin isophane), long-acting insulin (e.g., insulin degludec, insulin detemir, insulin glargine), amylinomimetic drugs (e.g., pramlintide), alpha-glucosidase inhibitors (e.g., acarbose, miglitol), biguanides (e.g., metformin), dopamine agonist (e.g., bromocriptine), DPP-4 inhibitors (e.g., alogliptin, linagliptin, saxagliptin, sitagliptin), glucagon-like peptides (e.g., albiglutide, dulaglutide, exenatide, e
- neurological and neurodegenerative disorder treating agents include opioid addiction (e.g., methadone, buprenorphine, naltrexone), nicotine addiction (e.g., bupropion, varenicline), alcohol addiction (e.g., naltrexone, acamprosate, disulfiram), cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamide), N-methyl-D-aspartate (NMDA) antagonists (e.g., memantine), dietary supplements (e.g., caprylidene), glutamate level reducers (e.g., riluzole), L-DOPA drugs (e.g., levodopa, carbidopa, benserazide, tolcapone, entacapone), dopamine agonists (e.g., bromocriptine, pergolide, pramipexole, ropinirole, piribedil, ca
- cardiovascular disease and blood disorder treating agents include antiplatelets (e.g., aspirin, clopidogrel, prasugrel, ticagrelor), angiotensin-converting enzyme inhibitors (e.g., benazepril, captpril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril), beta-blockers (e.g., acebutolol, atenolol, carvedilol, labetalol, metoprolol, nadolol, nebivolol, penbutolol, pindolol, propranolol), anticoagulants (e.g., warfarin, acenocoumarol, phenprocoumon, dabigatran, apixaban, edoxaban, rivaroxaban), clotting drugs (e.
- This example demonstrates the development of small-molecule PRMT5 inhibitors in an embodiment of the invention.
- the AlphaLISA technique (PerkinElmer, Waltham, Mass.) was adapted to an assay that could precisely quantify PRMT5 dimethylation of its substrate in a 384-well HTS platform ( FIG. 1 ).
- the AlphaLISA high-throughput screen comprises incubating a biotinylated substrate (e.g., histone H4), PRMT5, and a methyl donor (e.g., S-adenosyl-1-methionine (SAM)); PRMT5 dimethylates the biotinylated substrate and the dimethylated biotinylated substrate is recognized by Acceptor beads specific for the methylation site.
- a biotinylated substrate e.g., histone H4
- PRMT5 e.g., a methyl donor
- SAM S-adenosyl-1-methionine
- Donor beads comprising a tag (e.g., streptavadin) bind to the biotinylated substrate, and interaction between the Acceptor beads and Donor beads emits a signal (e.g., chemiluminescent signal), which can be detected.
- a signal e.g., chemiluminescent signal
- PRMT5 enzyme was purified with anti-Flag-M2 beads (Sigma-Aldrich, St. Louis, Mo.) from 293 cells overexpressing the Flag-PRMT5 protein (Wei et al., Proc Natl Acad Sci USA, 2013; 110: 13516-13521).
- the enzyme prep was diluted at 1:10 in assay buffer (30 mM Tris, pH 8.0, 1 mM DTT, 0.01% BSA, 0.01% Tween-20) before use.
- SAM S-adenosylmethionine
- DMSO dimethylsulfoxide
- Acceptor beads were then added at a final concentration of 20 ⁇ g/ml to the reaction mixture and the plate was incubated at room temperature (RT) for 1 hour. Donor beads were added at a final concentration of 20 ⁇ g/ml, and the plate was incubated at RT for 30 min. The reaction was run in 384 well plates. The plates were read using an ENVISIONTM Reader (PerkinElmer, Waltham, Mass.).
- a library of 10,000 small molecules was screened, and several potential compounds were identified to significantly inhibit PRMT5 methylation activity.
- the PRMT5 inhibitory activity of the compounds from the screen was confirmed using both AlphaLISA and an MTT [(3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide)] assay (PerkinElmer, Waltham, Mass.).
- MTT MTT
- cells were seeded at 90% confluence in 96-well plates and titrated with different dosages of compound (IIa) for 4 days. Media was then removed and 100 ⁇ l of MTT (Sigma-Aldrich, St. Louis, Mo.) was added per well. Cells were incubated for 2 hours at 37° C. before adding 100 ⁇ l of DMSO to each well and quantified with the SYNERGYTM H1 Multi-Mode Reader (BioTek Instruments Inc., Winooski, Vt.).
- the leading compounds were a compound of formula (II), specifically compound (IIa), a compound of formula (III), specifically compound (IIIa), and a compound of formula (IV), specifically compound (Iva).
- the IC 50 of compound (IIa) was 7.5 ⁇ M
- the IC 50 of compound (IIIa) was ⁇ 1.5 ⁇ M
- the IC 50 of compound (IVa) was 16.5 ⁇ M, as determined by the AlphaLISA (PerkinElmer, Waltham, Mass.) approach in vitro ( FIGS. 2A-2C ).
- Flag-p65 expressing cells were treated with 20 ⁇ M compound (IIa) for 24 hours, Flag-p65 was then pulled down with anti-Flag-M2 beads and analyzed with Western blot by probing with anti-dimethylated arginine ( FIG. 2B ). Compared to the untreated control, treatment with compound (IIa) significantly inhibited PRMT5-mediated p65 methylation.
- compound (IIa) did not inhibit or had at least a 10-fold higher IC 50 against other protein arginine methyltransferase family members when analyzed using the HotSpot radioisotope-based platform (Reaction Biology Corp, Malvern, Pa.) (Horiuchi et al., Assay Drug Dev. Technol., 2013; 11: 227-236).
- This example describes the lead optimization of compound (IIa) to identify small-molecule PRMT5 inhibitors with increased PRMT5 inhibitory activity compared to compound (IIa).
- the IC 50 of compound (Ia) was 2 ⁇ M in HT-29 and PANC1 cells
- the IC 50 of compound (If) was 7 ⁇ M in HT-29 and 8 ⁇ M in PANC1 cells
- the IC 50 of compound (Ig) was 7 ⁇ M in HT-29 and 11 ⁇ M in PANC1 cells
- the IC 50 of compound (Ib) was 11 ⁇ M in PANC1 cells ( FIGS. 3A and 3B ).
- pancreatic ductal adenocarcinoma cells The expression of PRMT5 was examined in pancreatic ductal adenocarcinoma cells at multiple stages of disease progression and in multiple colorectal cancer cell lines.
- Pancreatic control (HPNE) and cancer cell lines (PANC1, MiaPaCa2 and AsPC1) were grown in Dulbecco's Modified Eagle Medium (DMEM) (GE Healthcare, Little Chalfont, UK), supplemented with 1% of penicillin/streptomycin, 10% fetal bovine serum (FBS).
- DMEM Dulbecco's Modified Eagle Medium
- Colon control (FHC) and cancer (HT29, HCT116, and DLD1) cell lines were maintained in RPMI 1640 Medium (Roswell Park Memorial Institute Medium) (GE Healthcare, Little Chalfont, UK), containing 1% penicillin/streptomycin and 10% FBS, while FHC cells were cultured under the same condition with further addition of 25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 10 ng/ml cholera toxin, 0.005 mg/ml insulin, 0.005 mg/ml transferring, and 100 ng/ml hydrocortisone. All cell lines were cultured at 37° C. under 5% CO 2 .
- the expression of PRMT5 in the cell lines was determined by Western blotting using an anti-PRMT5 specific antibody. As shown in FIGS. 4A and 4C , expression of PRMT5 was markedly increased in each of the cell lines tested as compared to the corresponding control cell lines.
- the expression of PRMT5 was also analyzed in tissue microarray samples using immunohistochemistry.
- Pancreatic and colon cancer tissue microarrays with matched normal adjacent controls were acquired from OriGene Technologies (Rockville, Md.).
- the tissue microarrays were blocked using protein-blocking solution (Dako Corporation, Carpinteria, Calif.) for 30 min. All subsequent staining steps were performed using the Dako FLEX SYSTEM and an automated immunostainer. Incubations were carried out at room temperature and tris buffered saline containing 0.05% TWEENTM 20, pH 7.4 (Dako Corporation, Carpinteria, Calif.) was used for all the washes and diluents.
- Anti-PRMT5 primary antibody (Abcam, Cambridge, UK) was used to detect PRMT5 localization. Horseradish peroxidase conjugated to a secondary antibody was then used, followed by addition of the chromogen, which formed a brown precipitate at the binding site of secondary antibody. Imaging was done using an Aperio whole slide digital imaging system (Leica Biosystems, Buffalo Grove, Ill.). The system imaged all slides at 20 ⁇ magnification.
- PRMT5 was significantly higher in various stages of PDAC ( FIG. 4B ), particularly in the metastatic stage, as compared to the normal PDAC adjacent pancreatic tissue. Similarly, PRMT5 had much higher expression in samples ranging from inflammation, poylp, to the metastatic stage of CRC as compared to CRC adjacent normal colon tissue ( FIG. 4D ).
- PRMT5 promotes cell proliferation, anchorage-independent growth, and cell migration is cells with increased PRMT5 expression.
- PRMT5 The effect of PRMT5 on various characteristics of cancer cells, including cell proliferation, anchorage-independent growth, as well as, cell migration was examined.
- stable cell lines were generated, with either PRMT5 overexpression or shRNA knockdown of PRMT5 in PANC1 (PDAC) and HT29 (CRC) cell lines.
- PDAC PANC1
- CRC HT29
- Western blotting was carried out to verify the stable overexpression or knockdown of PRMT5 in these cell lines.
- FIG. 5A the stable cell lines showed desired expression level of PRMT5, as expected.
- the effect of PRMT5 on cell growth was determined.
- overexpression of PRMT5 led to a significant increase in the cell growth, while knockdown of PRMT5 showed opposite effect in both PDAC and HT29 derived stable lines, strongly suggesting that PRMT5 is a promoter for cell proliferation.
- the ability to form colonies suspended in soft agar is a characteristic of cancer cells.
- an anchorage-independent assay in soft agar was conducted. 2.5% and 1.25% agar were used to prepare the bottom and top layers of the soft agar, respectively. The bottom agar was added to each well of a 6-well plate. 2 ⁇ 10 5 cells for each cell line were then added and mixed into top agar solution and layered on top of the bottom layer. The plates were incubated for 10-20 days at 37° C. and 5% CO 2 . Images were captured using a Canon EOS Rebel T3i Digital SLR camera (Canon, Woodridge, Ill.) and quantification of colony size and number was performed using ImageJ.
- Migrated cells were fixed using 4% formaldehyde followed by crystal violet staining and counting using a microscope at 20 ⁇ magnification. The images were captured using a Canon EOS Rebel T3i Digital SLR camera (Canon, Woodridge, Ill.). As observed in FIG. 5F , overexpression of PRMT5 resulted in an increase in the number of cells that have been migrated, whereas shPRMT5 knockdown reduced this ability as compared to the control cells. Similar effects in CRC cell lines, as shown in FIG. 5G , were also observed. These results pointed out the important role that PRMT5 plays in cell migration.
- compound (Ia) had an IC 50 of 4.3 ⁇ M in PDAC cells (PANC1), and an IC 50 of 2.2 ⁇ M in CRC cells (HT29).
- mice were obtained from the In Vivo Therapeutics Core at Indiana University School of Medicine. After acclimation for 7 days, NSG mice (6-8 weeks old) were xenografted with mycoplasma -free PANC1 or HT29 cells subcutaneously (1 ⁇ 10 7 PANC1 or 3 ⁇ 10 6 HT29 cells used per mouse in 0.2 ml of a 1:1 mix of phosphate-buffered saline and MATRIGELTM) (BD Biosciences, San Jose, Calif.). Mice were randomized when tumor volumes reached about 100 mm 3 .
- mice were treated with either vehicle control or 20 mg/kg of compound (Ia) (drug stock dissolved in 1:1 CREMOPHORTM:ethanol solution) intraperitoneally 3 times per week. Tumor volumes and body weights were measured twice a week. The study was performed in accordance with the guidelines and standards of the Institutional Animal Care and Use Committee (IACUC). As shown in FIGS. 7A and 7B , injection of compound (Ia) did not visibly affect the body weight of the implanted mice, however, it led to significant tumor inhibition effect in both PANC1 ( FIG. 7C ) and HT29 ( FIG. 7D ) xenografted mice, demonstrating the strong anti-tumor efficacy of compound (Ia) against PRMT5 expressing cancers.
- IACUC Institutional Animal Care and Use Committee
- compound (IIa) had a range of IC 50 at 2-4 ⁇ M in PDAC cells (PANC1, MiaPaCa2 and AsPC1), and a range of IC 50 at 10-11 ⁇ M in CRC cells (HT29, HCT116 and DLD1).
- PDAC cells PANC1, MiaPaCa2 and AsPC1
- CRC cells HT29, HCT116 and DLD1
- a soft agar experiment was also performed to determine the effect of compound (IIa) on colony growth.
- treatment with compound (IIa) strongly inhibited colony formation of both PDAC and CRC cells.
- the commercially available PRMT5 inhibitor, EPZ015666 was much less effective as compared to compound (IIa), with a range of IC 50 at 50-95 ⁇ M for PDAC cells, and a range of IC 50 at 180-195 ⁇ M for CRC cells ( FIGS. 9A-9F ).
- mice were obtained from the In Vivo Therapeutics Core at Indiana University School of Medicine. After acclimation for 7 days, NSG mice (6-8 weeks old) were xenografted with mycoplasma -free PANC1 or HT29 cells subcutaneously (1 ⁇ 10 7 PANC1 or 3 ⁇ 10 6 HT29 cells used per mouse in 0.2 ml of a 1:1 mix of phosphate-buffered saline and MATRIGELTM) (BD Biosciences, San Jose, Calif.). Mice were randomized when tumor volumes reached about 100 mm 3 .
- mice were treated with either vehicle control or 20 mg/kg of compound (IIa) (drug stock dissolved in 1:1 CREMOPHORTM:ethanol solution) intraperitoneally 3 times per week. Tumor volumes and body weights were measured twice a week. The study was performed in accordance with the guidelines and standards of the Institutional Animal Care and Use Committee (IACUC). As shown in FIGS. 10A and 10B , injection of compound (IIa) did not visibly affect the body weight of the implanted mice, however, it led to significant tumor inhibition effect in both PANC1 ( FIG. 10C ) and HT29 ( FIG. 10D ) xenografted mice, demonstrating the strong anti-tumor efficacy of compound (IIa) against PRMT5 expressing cancers.
- IACUC Institutional Animal Care and Use Committee
- PRMT5 activates NF- ⁇ B through methylation of its p65 subunit in HEK293 cells (Wei et al., Proc Natl Acad Sci USA, 2013; 110: 13516-13521; Wei et al., Cell Cycle, 2013; 13: 32-41).
- overexpresion of PRMT5 enhances NF- ⁇ B activity, while PRMT5 knockdown causes the opposite effect in both PANC1 ( FIG. 11A ) and HT-29 ( FIG. 11B ) cells.
- NF- ⁇ B target genes e.g., pro-inflammatory cytokines TNF ⁇ and IL-8.
- NF- ⁇ B target genes e.g., pro-inflammatory cytokines TNF ⁇ and IL-8.
- HT29 and PANC1 cells were treated with or without compound (IIa), and target gene expression was analyzed by quantitative PCR.
- Treatment with compound (IIa) led to a significant decrease in the expression of TNF ⁇ and IL8 in both PANC1 ( FIGS. 11I-11J ) and HT29 cells ( FIGS. 11K-11L ), thus indicating that compound (IIa) decreased the PRMT5-mediated NF- ⁇ B-dependent gene activation.
- compound (IIa) showed significant efficacy in targeted reduction of NF- ⁇ B activation as well as its downstream gene activation in both PDAC and CRC cells.
- compound (IIIa) had a range of IC 50 at 8.5-12.5 ⁇ M in PDAC cells (PANC1, MiaPaCa2 and AsPC1), and a range of IC 50 at 5-11 ⁇ M in CRC cells (HT29, HCT116 and DLD1)
- compound (IVa) had a range of IC 50 at 22-51 ⁇ M in PDAC cells (PANC1, MiaPaCa2 and AsPC1), and a range of IC 50 at 35-50 ⁇ M in CRC cells (HT29, HCT116 and DLD1).
- This example demonstrates that PRMT5 activity is increased in neurological and neurodegenerative disorders.
- PRMT5 The expression of PRMT5 was analyzed by Western blot is samples from models of Alzheimer's disease. Briefly, samples were taken from non-transgenic B6 mice (6M) (control), hTau (humanized tau mice) (3M), hTau (6M), htau;Trem2 ⁇ / ⁇ mice (6M), hTau (18M), and APPPS1 amyloid mice. Cells overexpresssing PRMT5 were also used as a control. From these data, APPPS1 mice showed a significant increase in PRMT5 protein expression compared to age-matched B6 control mice ( FIGS. 13A and 13B ). Additionally, PRMT5 expression is increased along the aging of another Alzheimer's disease mouse model-hTau expression model and hTau/Trem2 ⁇ / ⁇ mouse model.
- Methamphetamine induces inflammation and activation of microglia through NF ⁇ B. Increased NF ⁇ B promotes inflammation and excitotoxicity are associated with neuronal damage and decrease in neurotransmitter (NT) levels of dopamine and serotonin.
- NT neurotransmitter
- PRMT5 could reduce neurotoxicity observed during post-meth administration and restore NT levels. This data suggests that compound (IIa) may be used to treat methamphetamine abuse.
- Rats were given methamphetamine treatment 7.5 mg/kg, 4 injections spaced out at 2 hours each. Then, 4 injections of 1 mg/kg of compound (IIa) or vehicle control were given at 12 hours, 24 hours, 36 hours, and 48 hours after the last methamphetamine injection. Rats were sacrificed 24 hours after the last injection and neurotransmitter levels were quantified in the striatum using high performance liquid chromatography (HPLC). In the group administered the compound of formula (II), an increase in the levels of NT levels were observed in the striatum region of the rats, thereby suggesting a neuroprotective effect ( FIGS. 14A and 14B ).
- the expression level of PRMT5 was analyzed in multiple tissues using the TiGER database.
- the expression profile PRMT5 in humans shows a significant expression of PRMT5 in heart tissue ( FIG. 15 ).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided are compounds of formulas (I), (II), (III), and (IV), which effectively inhibit protein arginine methyltransferase 5 (PRMT5). Also provided are methods of using the compounds, including a method of treating cancer, a method of inhibiting the activity of PRMT5 in a cell, and a method of treating a disease associated with increased activity of PRMT5.
Description
- This patent application is a continuation of U.S. application Ser. No. 16/344,644, which is a U.S. national counterpart application of international application serial No. PCT/US2017/058572 filed Oct. 26, 2017 which claims the benefit of U.S. Provisional Patent Application No. 62/534,969, filed Jul. 20, 2017, and U.S. Provisional Patent Application No. 62/413,341, filed Oct. 26, 2016, the disclosures of which are each incorporated in their entirety by reference.
- This invention was made with Government support under Grant Number TR001108 awarded by the National Institutes of Health. The Government has certain rights in the invention.
- Posttranslational modifications (PTMs) regulate protein function in eukaryotes and have been shown to play a role in a variety of cellular functions. In the past decade, research has greatly advanced the understanding of the role of PTMs of various signaling molecules that lead to the development of a variety of diseases, including cancers (Karve et al., J. Amino Acids, 2011; 2011: 207691). Methylation of lysine and arginine is one of the most critical PTMs seen in nature and is implicated in a number of cellular processes, such as DNA damage and repair, gene transcription and translation, and protein subcellular localization and translocation. Arginine methylation is carried out by a group of enzymes termed protein arginine methyltransferases. Amongst this family, protein arginine methyltransferase 5 (PRMT5) has been implicated in the development of a wide range of diseases. For example, the expression of PRMT5 is upregulated in a variety of cancers (e.g., liver cancer, pancreatic cancer, breast cancer, prostate cancer, and lung cancer, as well as lymphoma and melanoma), neurodegenerative disorders, inflammatory diseases, metabolic disorders, cardiovascular diseases, autoimmune disorders, and blood disorders.
- PRMT5 is an activator of NF-κB via
dimethylating arginine 30 of the p65 subunit of NF-κB. NF-κB is a critical eukaryotic transcription factor whose family consists of five members: RelA (p65), RelB, cRel, NF-κB1 (p50 and its precursor p105), and NF-κB2 (p52 and its precursor p100) (Ghosh et al., Annu Rev Immunol, 1998; 16: 225-260). NF-κB signaling can be classified into canonical and non-canonical pathways. The canonical pathway has been well established as a key contributor to development of both pancreatic ductal adenocarcinoma (PDAC) (Prabhu et al., Oncotarget, 2014; 5: 10969-10975; Liou et al., J Cell Biol, 2013; 202: 563-577) and colorectal cancer (CRC) (Agarwal et al., Oncogene, 2005; 24(6): 1021-31; Yu et al., Int J Colorectal Dis, 2004; 19: 18-22). In this pathway, inhibitor of κB (IκBα) sequesters the p65:p50 heterodimer in an inactive state in the cytoplasm. When a cell receives extracellular signals, such as stress or pro-inflammatory cytokines, IκB kinase phosphorylates IκBα, which leads to the degradation of IκB and release of the p65:p50 complex and the activation of NF-κB target genes (Gilmore, Oncogene, 2006; 25: 6680-6684). A number of these downstream NF-κB target genes have been implicated in a wide range of diseases including cancer, neurodegenerative disorders, inflammatory diseases, metabolic disorders, cardiovascular diseases, autoimmune disorders, and blood disorders. Increased NF-κB activation is shown to be associated with a poor disease prognosis, and linked to developing resistance against chemotherapy (Arora et al., J Biol Chem, 2013; 288: 21197-207; Lind et al., Surgery, 2001; 130: 363-69). - Accordingly, there is a need to identify new compounds for the treatment of PRMT5-associated diseases. This invention provides such compounds and associated methods.
- The invention provides compounds of formula (I), formula (II), formula (III), and formula (IV)
- in which R1, R2, R3, R4, R5, R6, R7, R8, R1A, R2A, R1B, R2B, R3B, R4B, R5B, R6B, R7B, R8B, R9B, R10B, X, X1A, X1B, m, and n are described herein. It has been discovered that compounds defined by formula (I), formula (II), formula (III), or formula (IV) are effective in inhibiting PRMT5, thereby making the compounds effective in treating diseases associated with increased expression or activity of PRMT5 (e.g., cancer).
- The invention further provides a method of treating a cancer in a subject comprising administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof to the subject.
- Also provided is a method of inhibiting the activity of PRMT5 in a cell comprising administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof to the cell.
- The invention also provides a method of treating a disease associated with increased expression or activity of PRMT5 in a subject comprising administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof to the subject.
-
FIG. 1 is a schematic illustration of the AlphaLISA technique for the identification of small-molecule PRMT5 inhibitors. Biotinylated substrate (histone H4) is incubated with PRMT5 and methyl donor, S-adenosyl-1-methionine (SAM). PRMT5 symmetrically dimethylates the third arginine (R3) on biotin-H4 to form biotin-H4R3me2. This product is recognized by Acceptor beads specific for this methylation site. Donor beads have a streptavidin tag and bind to biotin-H4. Interaction between the Acceptor and Donor beads emits a chemiluminescent signal, which is detected by an ENVISION™ Reader (PerkinElmer, Waltham, Mass.). The methylation activity of PRMT5 is proportional to the intensity of this signal. -
FIGS. 2A-D depict the experimental results of studies to determine the PRMT5 inhibitory activity of a compound of formula (II), a compound of formula (III), and a compound of formula (IV).FIG. 2A is a calculation of IC50 of compound (IIa) using AlphaLISA, which was found to be ˜7.5 μM.FIG. 2B is a calculation of IC50 of compound (IIIa) using AlphaLISA, which was found to be ˜1.5 μM.FIG. 2C is a calculation of IC50 of compound (IVa) using AlphaLISA, which was found to be ˜16.5 μM.FIG. 2D is a co-immunoprecipitation-Western blot, showing that treatment with 20 μM compound (IIa) for 24 hours inhibited the methylation of PRMT5 substrate, p65, in 293-WT-p65-Flag cell lines. Flag beads were used to pull down WT-p65-Flag and samples were then probed with anti-symmetric dimethyl arginine motif Ab (sdme-RG Ab) to detect dimethylation levels of the p65 subunit. -
FIGS. 3A-B depict the results of lead optimization studies to identify PRMT5 inhibitors.FIG. 3A is a table showing the calculation of IC50 of compounds (Ia), (If), and (Ig) compared to the parent compound (IIa) in HT-29 colon cancer cells.FIG. 3B is a table showing the calculation of IC50 of compounds (Ia), (Ib), (If), and (Ig) compared to the parent compound (IIa) in PANC1 pancreatic cancer cells. -
FIGS. 4A-D depict the experimental results of studies to determine the expression level of PRMT5 in multiple cancer types.FIG. 4A is a Western blot showing that PRMT5 protein expression is higher in PDAC cell lines, AsPC1, MiaPaCa2 and PANC1, as compared to a control pancreatic cell line, HPNE. β-actin was used as a loading control.FIG. 4B is immunohistochemical (IHC) staining demonstrating that PRMT5 protein expression is higher in PDAC tumor tissue as compared to the tissue from normal (i.e., non-cancerous) controls.FIG. 4C is a Western blot showing that PRMT5 protein expression is higher in CRC cell lines, HT29, HCT116 and DLD1, as compared to a control colon cell line, FHC. β-Actin was used as a loading control.FIG. 4D is IHC staining showing that PRMT5 protein expression was higher in the polyp stage and advanced stages of CRC, including stages II, III, IV, and the metastatic stage, compared to normal, non-cancerous colon tissue. -
FIGS. 5A-G depict the experimental results of studies to determine the effect of increased PRMT5 activity in cells.FIG. 5A is Western blot, confirming stable PRMT5 overexpression and shPRMT5 knockdown in PANC1 (left panel) and HT29 (right panel) cell lines. β-Actin was used as a loading control.FIGS. 5B and 5C are a cell proliferation assay, showing the effect of PRMT5 overexpression and shPRMT5 knockdown on cell growth in PANC1 (FIG. 5B ) and HT29 (FIG. 5C ) cell lines. Cell proliferation was significantly higher in the WT-PRMT5 cell lines, while shPRMT5 cells showed the opposite effect in both PANC1 and HT29 cell lines.FIGS. 5D and 5E are an anchorage-independent assay, showing the effect of PRMT5 overexpression and shPRMT5 knockdown on the colony size and colony number in PANC1 (FIG. 5D ) and HT29 (FIG. 5E ) cells. Anchorage-independent growth was significantly higher in the WT-PRMT5 cell lines, while significantly reduced in the shPRMT5 cells.FIGS. 5F and 5G are a cell migration assay, showing the effect of PRMT5 overexpression and shPRMT5 knockdown on cell migration in PANC1 (FIG. 5F ) and HT29 (FIG. 5G ) cell lines. The upper panels show representative pictures of the respective wells with 20× magnification. The lower panel denotes the quantification for the change in migration between the cell lines. Cell migration was significantly higher in the WT-PRMT5 overexpression cells, while significantly reduced in the shPRMT5 cells. The data represent the means±SD for three independent experiments. *P<0.05 vs. Ctrl group. -
FIGS. 6A-C depict the results of experiments to determine the inhibitory effect of compound (Ia) in multiple cancer types.FIG. 6A is an MTT assay in PDAC cells (PANC1), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (Ia).FIG. 6B is an MTT assay in CRC cells (HT29), showing that cell viability decreased significantly in the presence of increased concentrations of compound (Ia).FIG. 6C is a table, summarizing the IC50 values for compound (Ia) in PDAC and CRC cells, respectively. -
FIGS. 7A-D depict the results of experiments to determine the in vivo effect of compound (Ia).FIGS. 7A and 7B show that no significant changes in body weight were observed over the course of treatment in either PANC1 (FIG. 7A ) or HT29 (FIG. 7B ) model after treatment with 20 mg/kg of compound (Ia). (*P<0.05, n=4).FIGS. 7C and 7D are a tumor efficacy study, in which PANC1 (FIG. 7C ) or HT29 (FIG. 7D ) cells were subcutaneously implanted in NSG mice. Tumor volumes were measured and inhibition of tumor growth was observed upon treatment with 20 mg/kg of compound (Ia) intraperitoneally for 3×/week, as compared to the vehicle control. (*P<0.05, n=4). -
FIGS. 8A-H depict the results of experiments to determine the inhibitory effect of compound (IIa) in multiple cancer types.FIGS. 8A-C are an MTT assay in PDAC cells (PANC1, MiaPaCa2, and AsPC1), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (IIa).FIGS. 8D-F are an MTT assay in CRC cells (HT29, HCT116, and DLD1), showing that cell viability decreased significantly in the presence of increased concentrations of compound (IIa).FIG. 8G is a table, summarizing the IC50 values for compound (IIa) in PDAC and CRC cells, respectively.FIG. 8H is an anchorage-independent assay, showing that with increasing concentrations of compound (IIa), there was a significant decrease in the anchorage-independent growth ability in both PANC1 as well as HT29 cells. -
FIGS. 9A-G depict the results of experiments to determine the inhibitory effect of a commercially available PRMT5 inhibitor.FIGS. 9A-C are an MTT assay, showing that the commercially available PRMT5 inhibitor, EPZ015666, has lower efficacy to decrease cell viability in PDAC cells (PANC1, MiaPaCa2 and AsPC1) than that of compound (IIa).FIGS. 9D-F are an MTT assay, showing that EPZ015666 has lower efficacy to decrease cell viability in CRC cells (HT29, HCT116, and DLD1) than that of compound (IIa). The data represent the means±SD for three independent experiments. *P<0.05 vs. Ctrl group.FIG. 9G is a table summarizing the IC50 values for EPZ015666 in PDAC and CRC cell lines, respectively. -
FIGS. 10A-D depict the results of experiments to determine the in vivo effect of compound (IIa).FIGS. 10A and 10B show that no significant changes in body weight were observed over the course of treatment in either PANC1 (FIG. 10A ) or HT29 (FIG. 10B ) model after treatment with 20 mg/kg of compound (IIa). (*P<0.05, n=4).FIGS. 10C and 10D are a tumor efficacy study, in which PANC1 (FIG. 10C ) or HT29 (FIG. 10D ) cells were subcutaneously implanted in NSG mice. Tumor volumes were measured and inhibition of tumor growth was observed upon treatment with 20 mg/kg of compound (IIa) intraperitoneally for 3×/week, as compared to the vehicle control. (*P<0.05, n=4). -
FIGS. 11A-L depicts the results of experiments to determine the effect of compound (IIa) on PRMT5 induced NF-κB activation.FIGS. 11A and 11B are a NF-κB luciferase assay, showing that overexpression of WT-PRMT5 led to NF-κB activation, while shPRMT5 resulted in the opposite effect in both PANC1 (FIG. 11A ) and HT29 cells (FIG. 11B ).FIGS. 11C and 11D are a luciferase assay, showing a decrease in NF-κB activation with increasing concentrations of compound (IIa) in PANC1 (FIG. 11C ) and HT29 cells (FIG. 11D ), respectively. EPZ015666 needed a higher concentration in order to reach a similar level of NF-κB inhibition as that of compound (IIa). The data represent the means±SD for three independent experiments. *P<0.05 vs. Ctrl group.FIGS. 11E-H is a qPCR analysis, showing that overexpression of PRMT5 significantly enhanced IL-1β-triggered typical NF-κB target genes expression, TNFα and IL8, while shPRMT5 exhibited the opposite effect, in both PANC1 (FIGS. 11E and 11F ) and HT29 cells (FIGS. 11G and 11H ). The data represent the means±SD for three independent experiments. *P<0.05 vs. Ctrl group; #P<0.05 vs. Ctrl+IL-1β-treated group.FIGS. 11I-L are a qPCR analysis, showing that treatment with compound (IIa) dramatically decreased NF-κB target genes (TNFα and IL8) expression, in both PANC1 (FIGS. 11I and 11J ) and HT29 cells (FIGS. 11K and 11L ). The data represent the means±SD for three independent experiments. *P<0.5 vs. Ctrl group. -
FIGS. 12A-M depict the results of experiments to determine the inhibitory effect of compound (IIIa) and compound (IVa) in multiple cancer types.FIGS. 12A-12C are MTT assays in PDAC cells (PANC1 (FIG. 12A ), MiaPaCa2 (FIG. 12B ), and AsPC1 (FIG. 12C )), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (IIIa).FIGS. 12D-12F are MTT assays in CRC cells (HT29 (FIG. 12D ), HTC116 (FIG. 12E ), and DLD1 (FIG. 12F )), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (IIIa).FIGS. 12G-12I are MTT assays in PDAC cells (PANC1 (FIG. 12G ), MiaPaCa2 (FIG. 12H ), and AsPC1 (FIG. 12I )), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (IVa).FIGS. 12J-12L are MTT assays in CRC cells (HT29 (FIG. 12J ), HTC116 (FIG. 12K ), and DLD1 (FIG. 12L )), demonstrating that cell viability decreased significantly in the presence of increasing concentrations of compound (IVa).FIG. 12M is a table, summarizing the IC50 values for compound (IIIa) and compound (IVa) in PDAC and CRC cells, respectively. -
FIGS. 13A-B depict the results of experiments to identify the expression of PRMT5 in neurodegenerative disorders.FIG. 13A is a Western blot showing the expression of PRMT5 in cell lysate with PRMT5 overexpression (lane 2), non-transgenic B6 mice (6M) (lanes 3-5), hTau (humanized tau mice) (3M) (lanes 6-7), hTau (6M) (lanes 8-9), htau;Trem2−/− mice (6M) (lanes 10-11), hTau (18M) (lanes 12-13), and APPPS1 amyloid mice (lanes 14-15).FIG. 13B is a graph depicting the Western blot data of PRMT5 expression. *P<0.5 vs. Ctrl group. -
FIGS. 14A-B depicts the results of experiments to show the effect of compound (IIa) in neurological disorders.FIG. 14 shows the dopamine levels (FIG. 14A ) and serotonin levels (FIG. 14B ) in the striatum of rats treated with 7.5 mg/kg methamphetamine followed by 4 injections of 1 mg/kg compound (IIa) given at 12 hour intervals beginning 12 hours after methamphetamine treatment. (n=5). *P<0.05 vs. Ctrl group. -
FIG. 15 is a graph showing the expression level of PRMT5 in multiple human tissues, including heart tissue, as determined using the TiGER database. - The present invention is directed to compounds of formulas (I)-(IV) that have been discovered to be effective in inhibiting PRMT5, which enables the effective use of the compounds in treating various diseases associated with an increased expression or activity of PRMT5.
- In particular, the present invention provides a compound of formula (I)
- wherein
- R1 is hydrogen, halo, C1-C8 alkyl, C3-C6 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
- R2 is C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, C1-C8 alkoxy, C3-C6 cycloalkyloxy, aryloxy, halo, C1-C8 haloalkoxy, C1-C8 haloalkyl, haloaryl, haloaryloxy, —CN, —NO2, —(CH2)nC(O)R5, —(CH2)nCO2R5, —(CH2)nC(O)NR5R6, —(CH2)nNR5C(O)R6, or —(CH2)nNR5R6;
- R3 is hydroxy, C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, C1-C8 alkoxy, C3-C6 cycloalkyloxy, heterocycloalkyl, aryl, arylalkyl, heteroaryl, aryloxy, halo, C1-C8 haloalkyl, C1-C8 haloalkoxy, haloaryl, haloaryloxy, —CN, —NO2, —C(O)R5, —CO2R5, —C(O)NR5R6, —NR5C(O)R6, —(CH2)nNR5R6, —(CH2)nSO2NR5R6, —(CH2)nSO2R5, aryl; or
- two R3 moieties and the phenyl group to which they are attached form a naphthyl group that is optionally substituted;
- R4 is H, hydroxy, C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C1-C8 haloalkyl, —CN, —NO2, —(CH2)nNR5R6, heterocycloalkyl, aryl, or heteroaryl;
- X is a bond, —(CH2)oCR5R6—, —CR5R6(CH2)o—, —(CH2)oNR5—, —NR5(CH2)o—, —(CH2)oO—, or —O(CH2)o—,
- R5 and R6 are the same or different and each is H or C1-C8 alkyl;
- m, n, and o are the same or different and each is 0 or an integer from 1-5, or
- a pharmaceutically acceptable salt thereof.
- In an embodiment of the compound of formula (I), R1 is hydrogen, halo, C1-C8 alkyl, C3-C6 cycloalkyl, aryl, heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl. Preferably, R1 is halo, heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl.
- In any of the foregoing embodiments of the compound of formula (I), R2 is halo, C1-C8 haloalkoxy, C1-C8 haloalkyl, haloaryl, or haloaryloxy.
- In any of the foregoing embodiments of the compound of formula (I), R3 is C1-C8 alkyl, halo, or C1-C8 haloalkyl.
- In any of the foregoing embodiments of the compound of formula (I), R4 is H.
- In any of the foregoing embodiments of the compound of formula (I), X is a bond, —(CH2)oNR5—, or —NR5(CH2)o—. Preferably, X is a bond or —NH(CH2)o— (e.g., —NH(CH2)— or —NH(CH2)2—).
- In any of the foregoing embodiments of the compound of formula (I), m is 1.
- In any of the foregoing embodiments of the compound of formula (I), n is 0, 1, or 2.
- In any of the foregoing embodiments of the compound of formula (I), o is 1 or 2.
- In any of the foregoing embodiments of R5 and R6 are each H.
- In any of the foregoing embodiments of the compound of formula (I), R1 is heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl.
- In an embodiment of the compound of formula (I), R′ is halo, heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl; R2 is halo; R3 is C1-C8 alkyl or halo; R4 is H; X is a bond or —NR5(CH2)o—, R5 is H; m is 1; and o is 1 or 2.
- In an aspect of the invention, R1 is heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl; R2 is halo; R3 is C1-C8 alkyl or halo; R4 is H; X is a bond or —NR5(CH2)o—, R5 is H; m is 1; and o is 1 or 2.
- In any of the foregoing embodiments, the compound of formula (I) is in the form of a pharmaceutically acceptable salt.
- Exemplary compounds of formula (I) include compounds (Ia), (Ib), (Ic), (Id), (Ie), (If), and (Ig), are set forth below. Pharmaceutically acceptable salts of these exemplary compounds are also envisioned.
- The present invention also provides a compound of formula (II):
- wherein
- R5 is halo, heterocycloalkyl, or heteroaryl;
- R6 is C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, C1-C8 alkoxy, C3-C6 cycloalkyloxy, aryloxy, halo, C1-C8 haloalkoxy, C1-C8 haloalkyl, haloaryl,
- haloaryloxy, —CN, —NO2, —(CH2)nC(O)R9, —(CH2)nCO2R9, —(CH2)nC(O)NR9R10, —(CH2)nNR9C(O)R10, —(CH2)nNR9R10, —NR11(CH2)nNR9R10; or
- two R6 moieties and the phenyl group to which they are attached form a naphthyl group that is optionally substituted;
- R7 is hydroxy, C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, C1-C8 alkoxy, C3-C6 cycloalkyloxy, heterocycloalkyl, aryl, arylalkyl, heteroaryl, aryloxy, halo, C1-C8 haloalkyl, C1-C8 haloalkoxy, haloaryl,
- haloaryloxy, —CN, —NO2, —C(O)R9, —CO2R9, —C(O)NR9R10, —NR9C(O)R10, —(CH2)nNR9R10, —(CH2)nSO2NR9R10, —(CH2)nSO2R9, aryl; or
- two R7 moieties and the phenyl group to which they are attached form a naphthyl group that is optionally substituted;
- R8 is H, hydroxy, C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C1-C8 haloalkyl, —CN, —NO2, —(CH2)nNR9R10, heterocycloalkyl, aryl, or heteroaryl;
- X is a bond, —(CH2)oCR9R10—, —CR9R10(CH2)o—, —(CH2)oNR9—, —NR9(CH2)o—, —(CH2)oO—, or —O(CH2)o—,
- R9, R10, and R11 are the same or different and each is H or C1-C8 alkyl;
- m, n, and o are the same or different and each is 0 or an integer from 1-5, or
- a pharmaceutically acceptable salt thereof.
- In an embodiment of the compound of formula (II), R1 is hydrogen, halo, C1-C8 alkyl, C3-C6 cycloalkyl, aryl, heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl. Preferably, R1 is halo, heterocycloalkyl selected from the group consisting of isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl, or heteroaryl selected from the group consisting of pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl, (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl. In another embodiment of the compound of formula (II), R1 is substituted phenyl, as described herein, including phenyl substituted with C1-C8 alkyl, halo, or hydroxy. In a specific example, R1 is 3,4-di-C1-C8 alkylphenyl (e.g., 3,4-dimethylphenyl).
- In any of the foregoing embodiments of the compound of formula (II), R2 is halo, C1-C8 haloalkoxy, C1-C8 haloalkyl, haloaryl, or haloaryloxy. Alternatively, R2 is —NR7(CH2)nNR5R6. In an aspect of this embodiment, R5 and R6 are both C1-C8 alkyl, R7 is H, and/or n is 1 or 2. Preferably, R2 is —NR7(CH2)nNR5R6; R5 and R6 are methyl; R7 is H; and n is 2.
- In any of the foregoing embodiments of the compound of formula (II), R3 is C1-C8 alkyl, halo, or C1-C8 haloalkyl.
- In any of the foregoing embodiments of the compound of formula (II), R4 is H.
- In any of the foregoing embodiments of the compound of formula (II), X is a bond, —(CH2)oNR5—, or —NR5(CH2)o—. Preferably, X is a bond or —NH(CH2)o— (e.g., —NH—, —NH(CH2)— or —NH(CH2)2—).
- In any of the foregoing embodiments of the compound of formula (II), m is 0 or 1. In some preferred embodiments, m is 0, and the phenyl ring does not include any substituents.
- In any of the foregoing embodiments of the compound of formula (I), n is 0, 1, or 2.
- In any of the foregoing embodiments of the compound of formula (II), o is 0, 1, or 2.
- In any of the foregoing embodiments of the compound of formula (II) R5 and R6 are each H.
- An exemplary compound of formula (II) is compound (IIa). Pharmaceutically acceptable salts of the exemplary compound are also envisioned.
- In any of the foregoing embodiments of the compound of formula (I) or formula (II), IV preferably is not chloro. In a preferred embodiment, the compound of formula (I) or (II) is not 4,6-dichloro-1-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidine or 4,6-dichloro-1-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidine.
- The present invention also provides a compound of formula (III):
- wherein
- R1A and R2A are the same or different and each is hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, hydroxy, C1-C8 alkoxy, C3-C6 cycloalkyloxy, aryloxy, halo, C1-C8 haloalkoxy, C1-C8
- haloalkyl, haloaryl,
haloaryloxy, —CN, —NO2, —(CH2)nC(O)R11A, —(CH2)nCO2R11A, —(CH2)nC(O)NR11AR12A, —(CH2)nNR11AC(O)R12A, or —(CH2)nNR11AR12A; wherein each moiety other than hydrogen, hydroxy, halo, —CN, and —NO2 is optionally substituted; - X1A is O, S, or —NR11A;
- R11A and R12A are the same or different and each is H or C1-C8 alkyl;
- m is an integer from 1-4; and
- n is 0 or an integer from 1-5, or
- a pharmaceutically acceptable salt thereof.
- An exemplary compound of formula (III) is compound (IIIa). Pharmaceutically acceptable salts of the exemplary compound also are envisioned.
- The present invention further provides a compound of formula (IV):
- wherein
- R1B, R2B, R3B, R4B, R5B, R6B, R7B, R8B, R9B, and R10B are the same or different and each is hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, hydroxy, C1-C8 alkoxy, C3-C6 cycloalkyloxy, aryloxy, halo, C1-C8 haloalkoxy, C1-C8 haloalkyl, haloaryl,
- haloaryloxy, —CN, —NO2, —(CH2)nC(O)R11A, —(CH2)nCO2R11A, —(CH2)nC(O)NR11AR12A, —(CH2)nNR11AC(O)R12A, or —(CH2)nNR11AR12A; wherein each moiety other than hydrogen, hydroxy, halo, —CN, and —NO2 is optionally substituted;
- X1B is O, S, or —NR11B; and
- R11B and R12B are the same or different and each is H or C1-C8 alkyl, or
- a pharmaceutically acceptable salt thereof.
- An exemplary compound of formula (IV) is compound (IVa). Pharmaceutically acceptable salts of the exemplary compound are also envisioned.
- In any of the embodiments above, the term “alkyl” implies a straight-chain or branched alkyl substituent containing from, for example, from about 1 to about 8 carbon atoms, e.g., from about 1 to about 6 carbon atoms. Examples of alkyl group include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, and the like. This definition also applies wherever “alkyl” occurs as part of a group, such as, e.g., in C3-C6 cycloalkylalkyl, hydroxyalkyl, haloalkyl (e.g., monohaloalkyl, dihaloalkyl, and trihaloalkyl), cyanoalkyl, aminoalkyl, alkylamino, dialkylamino, arylalkyl, etc. The alkyl can be substituted or unsubstituted, as described herein. Even in instances in which the alkyl is an alkylene chain (e.g., —(CH2)n—), the alkyl group can be substituted or unsubstituted. An example of a substituted alkylene chain includes —CF2-cyclopropyl.
- In any of the embodiments above, the term “alkenyl,” as used herein, means a linear alkenyl substituent containing from, for example, about 2 to about 8 carbon atoms (branched alkenyls are about 3 to about 8 carbons atoms), e.g., from about 3 to about 6 carbon atoms (branched alkenyls are about 3 to about 6 carbons atoms). In accordance with an embodiment, the alkenyl group is a C2-C4 alkenyl. Examples of alkenyl group include ethenyl, allyl, 2-propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1-hexenyl, and the like. The alkenyl can be substituted or unsubstituted, as described herein.
- In any of the embodiments above, the term “cycloalkyl,” as used herein, means a cyclic alkyl moiety containing from, for example, 3 to 6 carbon atoms or from 5 to 6 carbon atoms. Examples of such moieties include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. The cycloalkyl can be substituted or unsubstituted, as described herein. For example, a substituted cycloalkyl includes a halo- or haloalkyl-substituted cyclopropyl, such as 2-fluorocyclopropyl, 2,2-difluorocyclopropyl, 1-(trifluoromethyl)cyclopropyl, and 2-(trifluoromethyl)cyclopropyl.
- In any of the embodiments above, the term “hydroxy” refers to the group —OH.
- In any of the embodiments above, the terms “alkoxy” and “cycloalkyloxy” embrace linear or branched alkyl and cycloalkyl groups, respectively, that are attached to a divalent oxygen. The alkyl and cycloalkyl groups are the same as described herein. The term “aryloxy” refers to substituents that have an aryl group attached to divalent oxygen. The aryl group is the same as described herein.
- In any of the embodiments above, the term “halo” refers to a halogen selected from fluorine, chlorine, bromine, and iodine.
- In any of the embodiments above, the term “aryl” refers to a mono, bi, or tricyclic carbocyclic ring system having one, two, or three aromatic rings, for example, phenyl, naphthyl, anthracenyl, or biphenyl. The term “aryl” refers to an unsubstituted or substituted aromatic carbocyclic moiety, as commonly understood in the art, and includes monocyclic and polycyclic aromatics such as, for example, phenyl, biphenyl, naphthyl, anthracenyl, pyrenyl, and the like. An aryl moiety generally contains from, for example, 6 to 30 carbon atoms, from 6 to 18 carbon atoms, from 6 to 14 carbon atoms, or from 6 to 10 carbon atoms. It is understood that the term aryl includes carbocyclic moieties that are planar and comprise 4n+2 π electrons, according to Hückel's Rule, wherein n=1, 2, or 3. This definition also applies wherever “aryl” occurs as part of a group, such as, e.g., in haloaryl (e.g., monohaloaryl, dihaloaryl, and trihaloaryl), arylalkyl, etc. The aryl can be substituted or unsubstituted, as described herein.
- In any of the embodiments above, the term “heteroaryl” refers to aromatic 5 or 6 membered monocyclic groups, 9 or 10 membered bicyclic groups, and 11 to 14 membered tricyclic groups which have at least one heteroatom (O, S, or N) in at least one of the rings. Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen atoms may optionally be quaternized. Heteroaryl groups which are bicyclic or tricyclic must include at least one fully aromatic ring but the other fused ring or rings may be aromatic or non-aromatic. The heteroaryl group may be attached at any available nitrogen or carbon atom of any ring. Illustrative examples of heteroaryl groups are pyridinyl, pyridazinyl, pyrimidyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)- and (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl, and oxadiazolyl. The heteroaryl can be substituted or unsubstituted, as described herein.
- The term “heterocycloalkyl” means a stable, saturated, or partially unsaturated monocyclic, bicyclic, and spiro ring system containing 3 to 7 ring members of carbon atoms and other atoms selected from nitrogen, sulfur, and/or oxygen. In an aspect, a heterocycloalkyl is a 5, 6, or 7-membered monocyclic ring and contains one, two, or three heteroatoms selected from nitrogen, oxygen, and sulfur. The heterocycloalkyl may be attached to the parent structure through a carbon atom or through any heteroatom of the heterocycloalkyl that results in a stable structure. Examples of such heterocycloalkyl rings are isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, piperidyl, oxazolyl, and morpholinyl. The heterocycloalkyl can be substituted or unsubstituted, as described herein.
- In any of the embodiments above, the alkyl, alkoxy, and alkylamino groups can be linear or branched.
- In other aspects, any substituent that is not hydrogen (e.g., C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or heterocycloalkyl) can be an optionally substituted moiety. The substituted moiety typically comprises at least one substituent (e.g., 1, 2, 3, 4, 5, 6, etc.) in any suitable position (e.g., 1-, 2-, 3-, 4-, 5-, or 6-position, etc.). When an aryl group is substituted with a substituent, e.g., halo, amino, alkyl, OH, alkoxy, and others, the aromatic ring hydrogen is replaced with the substituent and this can take place in any of the available hydrogens, e.g., 2, 3, 4, 5, and/or 6-position wherein the 1-position is the point of attachment of the aryl group in the compound of the present invention. Suitable substituents include, e.g., halo, alkyl, alkenyl, alkynyl, hydroxy, nitro, cyano, amino, alkylamino, alkoxy, aryloxy, aralkoxy, carboxyl, carboxyalkyl, carboxyalkyloxy, amido, alkylamido, haloalkylamido, aryl, heteroaryl, and heterocycloalkyl, each of which is described herein. In some instances, the substituent is at least one alkyl, halo, and/or haloalkyl (e.g., 1 or 2).
- In any of the embodiments above, whenever a range of the number of atoms in a structure is indicated (e.g., a C1-12, C1-8, C1-6, or C1-4 alkyl, cycloalkyl, etc.), it is specifically contemplated that any sub-range or individual number of carbon atoms falling within the indicated range also can be used. Thus, for instance, the recitation of a range of 1-8 carbon atoms (e.g., C1-C8), 1-6 carbon atoms (e.g., C1-C6), 1-4 carbon atoms (e.g., C1-C4), 1-3 carbon atoms (e.g., C1-C3), or 2-8 carbon atoms (e.g., C2-C8) as used with respect to any chemical group (e.g., alkyl, cycloalkyl, etc.) referenced herein encompasses and specifically describes 1, 2, 3, 4, 5, 6, 7, and/or 8 carbon atoms, as appropriate, as well as any sub-range thereof (e.g., 1-2 carbon atoms, 1-3 carbon atoms, 1-4 carbon atoms, 1-5 carbon atoms, 1-6 carbon atoms, 1-7 carbon atoms, 1-8 carbon atoms, 2-3 carbon atoms, 2-4 carbon atoms, 2-5 carbon atoms, 2-6 carbon atoms, 2-7 carbon atoms, 2-8 carbon atoms, 3-4 carbon atoms, 3-5 carbon atoms, 3-6 carbon atoms, 3-7 carbon atoms, 3-8 carbon atoms, 4-5 carbon atoms, 4-6 carbon atoms, 4-7 carbon atoms, 4-8 carbon atoms, etc., as appropriate).
- The subscript “m” represent the number of substituents of R3, in which each substituent of R3, can be the same or different. The subscripts m can be either 0 or an integer from 1-5 (i.e., 1, 2, 3, 4, or 5). When m is 0, then the R3 is not present in the compound of formula (I) or (II). The subscripts “n” and “o” represent the number of methylene repeat units. The subscripts n and o are either 0 or an integer from 1-5 (i.e., 1, 2, 3, 4, or 5). When n or o is 0, then the respective moiety does not contain any methylene repeat units.
- In any of the embodiments above, the phrase “salt” or “pharmaceutically acceptable salt” is intended to include nontoxic salts synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two. For example, an inorganic acid (e.g., hydrochloric acid, sulfuric acid, phosphoric acid, or hydrobromic acid), an organic acid (e.g., oxalic acid, malonic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, or benzylsulfonic acid), an inorganic base (e.g., sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, or ammonium hydroxide), an organic base (e.g., methylamine, diethylamine, triethylamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, guanidine, choline, or cinchonine), or an amino acid (e.g., lysine, arginine, or alanine) can be used. Generally, nonaqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typical. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, Pa., 1990, p. 1445, and Journal of Pharmaceutical Science, 66, 2-19 (1977). For example, they can be a salt of an alkali metal (e.g., sodium or potassium), alkaline earth metal (e.g., calcium), or ammonium.
- The methods described herein comprise administering a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof in the form of a pharmaceutical composition. In particular, a pharmaceutical composition will comprise at least one compound of formulas (I)-(IV), or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutically acceptable excipients described herein, for example, vehicles, adjuvants, carriers or diluents, are well-known to those who are skilled in the art and are readily available to the public. Typically, the pharmaceutically acceptable carrier is one that is chemically inert to the active compounds and one that has no detrimental side effects or toxicity under the conditions of use.
- The pharmaceutical compositions can be administered as oral, sublingual, transdermal, subcutaneous, topical, absorption through epithelial or mucocutaneous linings, intravenous, intranasal, intraarterial, intramuscular, intratumoral, peritumoral, interperitoneal, intrathecal, rectal, vaginal, or aerosol formulations. In some aspects, the pharmaceutical composition is administered orally or intravenously.
- In accordance with any of the embodiments, the compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof can be administered orally to a subject in need thereof. Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice and include an additive, such as cyclodextrin (e.g., α-, β-, or γ-cyclodextrin, hydroxypropyl cyclodextrin) or polyethylene glycol (e.g., PEG400); (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions and gels. Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent. Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and cornstarch. Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.
- Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, glycerol ketals, such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, such as poly(ethyleneglycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.
- Oils, which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters. Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylene-polypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-beta-aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (3) mixtures thereof.
- The parenteral formulations will typically contain from about 0.5 to about 25% by weight of the inhibitors in solution. Suitable preservatives and buffers can be used in such formulations. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations ranges from about 5 to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
- The inhibitors may be made into injectable formulations. The requirements for effective pharmaceutical carriers for injectable compositions are well known to those of ordinary skill in the art. See Pharmaceutics and Pharmacy Practice, J. B. Lippincott Co., Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986).
- Topically applied compositions are generally in the form of liquids (e.g., mouthwash), creams, pastes, lotions and gels. Topical administration includes application to the oral mucosa, which includes the oral cavity, oral epithelium, palate, gingival, and the nasal mucosa. In some embodiments, the composition contains at least one active component and a suitable vehicle or carrier. It may also contain other components, such as an anti-irritant. The carrier can be a liquid, solid or semi-solid. In embodiments, the composition is an aqueous solution, such as a mouthwash. Alternatively, the composition can be a dispersion, emulsion, gel, lotion or cream vehicle for the various components. In one embodiment, the primary vehicle is water or a biocompatible solvent that is substantially neutral or that has been rendered substantially neutral. The liquid vehicle can include other materials, such as buffers, alcohols, glycerin, and mineral oils with various emulsifiers or dispersing agents as known in the art to obtain the desired pH, consistency and viscosity. It is possible that the compositions can be produced as solids, such as powders or granules. The solids can be applied directly or dissolved in water or a biocompatible solvent prior to use to form a solution that is substantially neutral or that has been rendered substantially neutral and that can then be applied to the target site. In embodiments of the invention, the vehicle for topical application to the skin can include water, buffered solutions, various alcohols, glycols such as glycerin, lipid materials such as fatty acids, mineral oils, phosphoglycerides, collagen, gelatin and silicone based materials.
- The compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof, alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer
- The dose administered to the subject, particularly human and other mammals, in accordance with the present invention should be sufficient to affect the desired response. One skilled in the art will recognize that dosage will depend upon a variety of factors, including the age, condition or disease state, predisposition to disease, genetic defect or defects, and body weight of the mammal. The size of the dose will also be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular inhibitor and the desired effect. It will be appreciated by one of skill in the art that various conditions or disease states may require prolonged treatment involving multiple administrations.
- The inventive methods comprise administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof for the treatment of a disease. As used herein, the terms “treatment,” “treated,” “treating,” and the like refer to obtaining a desired pharmacologic and/or physiologic effect. Preferably, the effect is therapeutic, i.e., the effect partially or completely cures a disease and/or adverse symptom attributable to the disease. A “pharmaceutically effective amount” means an amount sufficient to show a meaningful benefit in an individual, e.g., promoting at least one aspect of tumor cell cytotoxicity (e.g., inhibition of growth, inhibiting survival of a cancer cell, reducing proliferation, reducing size and/or mass of a tumor (e.g., solid tumor)), or treatment, healing, prevention, delay of onset, halting, or amelioration of other relevant medical condition(s) associated with a particular cancer. The meaningful benefit observed in the patient can be to any suitable degree (e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or 90% or more). In some aspects, one or more symptoms of the cancer are prevented, reduced, halted, or eliminated subsequent to administration of a compound of formula (I), formula (II), formula (III), or formula (IV), including compounds of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (IIa), (IIIa), and (IVa), or a pharmaceutically acceptable salt thereof, thereby effectively treating the cancer to at least some degree.
- Effective amounts can vary depending upon the biological effect desired in the individual, condition to be treated, and/or the specific characteristics of the compound of formula (I), formula (II), formula (III), or formula (IV), including compounds of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (IIa), (IIIa), and (IVa), or a pharmaceutically acceptable salt thereof, and the individual. In this respect, any suitable dose of the compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof can be administered to the patient (e.g., human), according to the type of disease (e.g., cancer) to be treated. Various general considerations taken into account in determining the “effective amount” are known to those of skill in the art and are described, e.g., in Gilman et al., Eds., Goodman And Gilman's: The Pharmacological Bases of Therapeutics, 8th ed., Pergamon Press, 1990; and Remington's Pharmaceutical Sciences, 17th Ed., Mack Publishing Co., Easton, Pa., 1990, each of which is herein incorporated by reference. The dose of the compound of formula (I), formula (II), formula (III), or formula (IV), including compounds of formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (IIa), (IIIa), and (IVa), or a pharmaceutically acceptable salt thereof desirably comprises about 0.1 mg per kilogram (kg) of the body weight of the mammal (mg/kg) to about 400 mg/kg (e.g., about 0.75 mg/kg, about 5 mg/kg, about 30 mg/kg, about 75 mg/kg, about 100 mg/kg, about 200 mg/kg, or about 300 mg/kg). In another embodiment, the dose of the compound formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof, comprises about 0.5 mg/kg to about 300 mg/kg (e.g., about 0.75 mg/kg, about 5 mg/kg, about 50 mg/kg, about 100 mg/kg, or about 200 mg/kg), about 10 mg/kg to about 200 mg/kg (e.g., about 25 mg/kg, about 75 mg/kg, or about 150 mg/kg), or about 50 mg/kg to about 100 mg/kg (e.g., about 60 mg/kg, about 70 mg/kg, or about 90 mg/kg).
- In an aspect of the invention, a compound of formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV), or a pharmaceutically acceptable salt thereof can inhibit the activity of PRMT5 in a cell. Elevated activity of PRMT5 has been described in the art for multiple disorders, including various types of cancer (Wei et al., Proc. Natl. Acad. Sci., 110(33): 13516-13521 (2013); Lu et al., Cancer Res., 75(18): 3692-3695 (2015)). While not wishing to be bound by any particular theory, it is believed that inhibition of PRMT5 by a compound of formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV), or a pharmaceutically acceptable salt thereof causes a decrease in the activation of nuclear factor κB (NF-κB) leading to a decrease in tumor progression.
- As used herein the terms “elevated activity,” “increased activity” and the like refers to any increase in the enzymatic activity of the protein, any increase in the total amount of protein present, or any increase in the level of gene (e.g., mRNA, RNA, DNA) expression. Increased activity is measured against a control sample. For example, the mRNA level of PRMT5 is measured in a cancer cell and is compared to the PRMT5 mRNA level in a non-cancer control cell of the same tissue type. Methods to identify subjects or cells with increased activity of a protein, increased level of a protein, or increased expression of a gene are routine in the art and include, for example, Western blotting, RT-PCR, PCR, quantitative PCR, ELISA, and enzyme assays. Additionally, the methods described herein can also be used by a person of ordinary skill in the art to determine increased activity of a protein, increased level of a protein or increased expression of a gene.
- One aspect of the inventive method provides a method of treating cancer in a subject comprising administering a pharmaceutically effective amount of formula (I), formula (II), formula (III), or formula (IV), which includes the compounds of formulas (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (IIa), (IIIa), and (IVa), or a pharmaceutically acceptable salt thereof, to the subject whereby the cancer is treated.
- As used herein the term “subject” includes any living organism that would benefit from inhibition of PRMT5. In certain embodiments the subject is a mammal. Mammals include, but are not limited to, the order Rodentia, such as mice, and the order Logomorpha, such as rabbits. In some aspects, the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs), Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses). In some aspects, the mammals are of the order Primates, Ceboids, or Simioids (monkeys) or of the order Anthropoids (humans and apes). In embodiments of the invention, the subject is a human.
- The type of cancer is not particularly limited. In certain embodiments the cancer is characterized as a cancer that has increased activity of PRMT5 compared to a non-cancer sample of the same tissue type. The identification of a cancer that has increased activity of PRMT5 can be readily identified by a person of ordinary skill in the art using routine methods (e.g., Western blot, enzyme-linked immunosorbent assay (ELISA), or polymerase chain reaction (PCR)), including the methods described herein. In another embodiment the cancer is characterized as a cancer that has increased activity of NF-κB compared to a non-cancer sample of the same tissue type. The identification of a cancer that has increased activity of NF-κB can be readily identified by a person of ordinary skill in the art using routine methods (e.g., Western blot, ELISA, or PCR). In a further embodiment of the invention the cancer has increased activity of PRMT5 and increased activity of NF-κB.
- Examples of cancers treatable with the inventive method include cancers of the head and neck, eye, skin, mouth, throat, esophagus, chest, bone, lung, colon, sigmoid, rectum, stomach, prostate, breast, ovaries, kidney, liver, pancreas, brain, intestine, heart, or adrenals. More particularly, cancers include solid tumor, sarcoma, carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendothelio sarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, Kaposi's sarcoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, retinoblastoma, a blood-borne tumor, acute lymphoblastic leukemia, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, acutenonlymphocyctic leukemia, acute undifferentiated leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, or multiple myeloma. See, e.g., Harrison's Principles of Internal Medicine, Eugene Braunwald et al., Eds., pp. 491 762 (15th ed. 2001). In some aspects, the cancer is a solid tumor. In accordance with an embodiment, the cancer is selected from gastrointestinal cancer, skin cancer, lung cancer, brain cancer, ovarian cancer, prostate cancer, lymphoma, melanoma, and breast cancer. In another embodiment, the cancer is pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, pancreatic cancer, or liver cancer.
- Another aspect of the inventive method provides a method of inhibiting the activity of PRMT5 in a cell, comprising administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof to the cell, whereby the activity of PRMT5 is inhibited. Inhibition of PRMT5 includes any decrease in methyltransferase activity compared to an untreated or control treated subject. Inhibition or PRMT5 also includes any decrease in the protein level of PRMT5 in a subject compared to an untreated or control treated subject. Inhibition of PRMT5 can be demonstrated, for example, by a decrease in NF-κB activity.
- In certain embodiments the cell is treated in vitro or ex vivo. In other embodiments the cell is in a subject.
- The type of cell in which PRMT5 is inhibited is not particularly limited. In certain embodiments, the cell is a cancer cell. The cancer cell can be from any cancer type described in the foregoing. In certain embodiments the cancer cell is from PDAC, colorectal cancer, pancreatic cancer, or liver cancer.
- PRMT5 activity has been shown to be increased in a variety of disease, and inhibition of PRMT5 has been described in the art as a viable treatment of multiple diseases, including autoimmune diseases, inflammatory disease, metabolic disorders, neurological and neurodegenerative disorders, cardiovascular diseases, and blood disorders (Kim et al., Mediators Inflamm., 2016; Published online doi: 10.1155/2016/4028353; Stopa et al., Cell Mol. Life Sci., 2015; 72(11): 2041-2059; Karkhanis et al., Trends Biochem Sci., 2011; 36(12): 633-641; Likhite et al., Science Signaling, 2015; 8(402) ra115; Wei et al., Cell Cycle, 2013; 13: 32-41; Kryukov et al. Science, 2016; epub 10.1126/science.aad5214). Therefore, another aspect of the invention provides a method of treating a disease associated with increased expression of PRMT5 in a subject, comprising administering a pharmaceutically effective amount of a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof to the subject, thereby treating the disease. Suitable diseases that can be treated include, for example, autoimmune diseases, inflammatory disease, metabolic disorders, neurological and neurodegenerative disorders, cardiovascular diseases, and blood disorders.
- Examples of autoimmune diseases treatable with the inventive method include alopecia areata, autoimmune hemolytic anemia, autoimmune hepatitis, dermatomyositis, diabetes (type 1), juvenile idiopathic arthritis, glomerulonephritis, Graves' disease, Guillain-Barré syndrome, idiopathic thrombocytopenic purpura, myasthenia gravis, myocarditis, multiple sclerosis, pemphigus/pemphigoid, pernicious anemia, polyarteritis nodosa, polymyositis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, scleroderma/systemic sclerosis, Sjögren's syndrome, systemic lupus erythematosus, thyroiditis, uveitis, vitiligo, and granulomatosis with polyangiitis (Wegener's).
- Examples of inflammatory diseases treatable with the inventive method include ankylosing spondylitis, arthritis (e.g., osteoarthritis, rheumatoid arthritis (RA), psoriatic arthritis), gout, eczema, gastritis, splenitis, sinusitis, hepatitis, nephritis, psoriasis, vasculitis, atherosclerosis, sarcoidosis, pleurisy, asthma, atherosclerosis, Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), systemic lupus erythematous (SLE), nephritis, and ulcerative colitis.
- Examples of metabolic disorders treatable with the inventive method include diabetes (
type 1 and type 2), phenylketonuira, and obesity. - Examples of neurological and neurodegenerative disorders treatable with the inventive method include drug abuse (e.g., methamphetamine addiction), Alzheimer's disease, amyotrophic lateral sclerosis, Angelman syndrome, Asperger syndrome, autism, bipolar disorder, cerebral arteriosclerosis, Charcot-Marie-Tooth disease, chronic pain, Cushing's syndrome, Creutzfeldt-Jakob disease, dementia, Huntington's disease, inclusion body myositis, Parkinson's disease, and Reye syndrome.
- Examples of cardiovascular disorders treatable with the inventive method include coronary artery disease, angina, myocardial infarction, stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.
- Examples of blood disorders treatable with the inventive method include anemia, bleeding disorders, hemophilia, sickle cell anemia, hemoglobinopathy, β-thalassemia, and blood clots.
- In certain embodiments of this method, a compound formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV), or a pharmaceutically acceptable salt thereof can be co-administered with an anti-cancer agent (e.g., a chemotherapeutic agent) and/or radiation therapy. In an aspect, the method comprises administering an amount of a compound or salt that is effective to sensitize the cancer cells to one or more therapeutic regimens (e.g., chemotherapy or radiation therapy). The terms “co-administered” or “co-administration” refer to simultaneous or sequential administration. A compound may be administered before, concurrently with, or after administration of another compound.
- One or more than one, e.g., two, three, or more anti-cancer agents can be administered. In this regard, the present invention is directed a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination of a compound of formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV), or a pharmaceutically acceptable salt thereof and at least one anti-cancer agent (e.g., chemotherapeutic agent).
- Examples of anti-cancer agents include platinum compounds (e.g., cisplatin, carboplatin, oxaliplatin), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, nitrogen mustard, thiotepa, melphalan, busulfan, procarbazine, streptozocin, temozolomide, dacarbazine, bendamustine), antitumor antibiotics (e.g., daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, bleomycin, mytomycin C, plicamycin, dactinomycin), taxanes (e.g., paclitaxel and docetaxel), antimetabolites (e.g., 5-fluorouracil, cytarabine, premetrexed, thioguanine, floxuridine, capecitabine, and methotrexate), nucleoside analogues (e.g., fludarabine, clofarabine, cladribine, pentostatin, nelarabine), topoisomerase inhibitors (e.g., topotecan and irinotecan), hypomethylating agents (e.g., azacitidine and decitabine), proteasome inhibitors (e.g., bortezomib), epipodophyllotoxins (e.g., etoposide and teniposide), DNA synthesis inhibitors (e.g., hydroxyurea), vinca alkaloids (e.g., vicristine, vindesine, vinorelbine, and vinblastine), tyrosine kinase inhibitors (e.g., imatinib, dasatinib, nilotinib, sorafenib, sunitinib), monoclonal antibodies (e.g., rituximab, cetuximab, panetumumab, tositumomab, trastuzumab, alemtuzumab, gemtuzumab ozogamicin, bevacizumab), nitrosoureas (e.g., carmustine, fotemustine, and lomustine), enzymes (e.g., L-Asparaginase), biological agents (e.g., interferons and interleukins), hexamethylmelamine, mitotane, angiogenesis inhibitors (e.g., thalidomide, lenalidomide), steroids (e.g., prednisone, dexamethasone, and prednisolone), hormonal agents (e.g., tamoxifen, raloxifene, leuprolide, bicaluatmide, granisetron, flutamide), aromatase inhibitors (e.g., letrozole and anastrozole), arsenic trioxide, tretinoin, nonselective cyclooxygenase inhibitors (e.g., nonsteroidal anti-inflammatory agents, salicylates, aspirin, piroxicam, ibuprofen, indomethacin, naprosyn, diclofenac, tolmetin, ketoprofen, nabumetone, oxaprozin), selective cyclooxygenase-2 (COX-2) inhibitors, or any combination thereof.
- In other embodiments of this method, a compound formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV), or a pharmaceutically acceptable salt thereof can be co-administered with an agent that treats a disease associated with increased activity of PRMT5.
- One or more than one, e.g., two, three, or more agents can be administered. In this regard, the present invention is directed a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination of a compound of formula (I), a compound of formula (II), a compound of formula (III), or a compound of formula (IV), or a pharmaceutically acceptable salt thereof and at least one other PRMT5 disease modifying agent.
- Examples of autoimmune disease and inflammatory disease treating agents include alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, nitrogen mustard, thiotepa, melphalan, busulfan, procarbazine, streptozocin, temozolomide, dacarbazine, bendamustine), antimetabolites (e.g., methotrexate, azathioprine, mercaptopurine, flurouracil), cytotoxic antibiotics (e.g., daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, bleomycin, mytomycin C, plicamycin, dactinomycin), polyclonal antibodies (e.g., atgam, thymoglobuline), monoclonal antibodies (e.g., muromonab-CD3, basiliximab, daclizumab, omalizumab), calcinurin and mTOR inhibitors (e.g., ciclosporin, tacrolumus, sirolimus, everolimus)), biological agents (e.g., interferons and interleukins), opioids, TNF binding proteins (e.g., infliximab, etanercept, adalimumab, curcumin catechins), nonselective cyclooxygenase inhibitors (e.g., nonsteroidal anti-inflammatory agents, salicylates, aspirin, piroxicam, ibuprofen, indomethacin, naprosyn, diclofenac, tolmetin, ketoprofen, nabumetone, oxaprozin), selective cyclooxygenase-2 (COX-2) inhibitors, disease-modifying antirheumatic drugs (DMARDS) (e.g., hydroxychloroquine, leflunomide, minocycline, anakinra, abatacept, azathioprine, tofacitinib), steroids (e.g., glucocorticoids, cortisol, prednisone, dexamethasone, and prednisolone), or any combination thereof.
- Examples of metabolic disorder treating agents include short-acting insulin (e.g., humulin, novolin), rapid-acting insulin (e.g., insulin aspart, insulin glulisine, insulin lispro), intermediate acting insulin (e.g., insulin isophane), long-acting insulin (e.g., insulin degludec, insulin detemir, insulin glargine), amylinomimetic drugs (e.g., pramlintide), alpha-glucosidase inhibitors (e.g., acarbose, miglitol), biguanides (e.g., metformin), dopamine agonist (e.g., bromocriptine), DPP-4 inhibitors (e.g., alogliptin, linagliptin, saxagliptin, sitagliptin), glucagon-like peptides (e.g., albiglutide, dulaglutide, exenatide, liraglutide), meglitinides (e.g., nateglinide, repaglinide),
sodium glucose transporter 2 inhibitors (e.g., dapagliflozin, canagliflozin, empagliflozin), sulfonylureas (e.g., glimerpiride, gliclazide, glipizide, glyburide, chlorpropamide, tolazamide, tolbutamide), thiazolidinediones (e.g., rosiglitazone, pioglitazone), or any combination thereof. - Examples of neurological and neurodegenerative disorder treating agents include opioid addiction (e.g., methadone, buprenorphine, naltrexone), nicotine addiction (e.g., bupropion, varenicline), alcohol addiction (e.g., naltrexone, acamprosate, disulfiram), cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamide), N-methyl-D-aspartate (NMDA) antagonists (e.g., memantine), dietary supplements (e.g., caprylidene), glutamate level reducers (e.g., riluzole), L-DOPA drugs (e.g., levodopa, carbidopa, benserazide, tolcapone, entacapone), dopamine agonists (e.g., bromocriptine, pergolide, pramipexole, ropinirole, piribedil, cabergoline, apomorphine and lisuride), MAO-B inhibitors (e.g., safinamide, selegiline, rasagiline), or any combination thereof.
- Examples of cardiovascular disease and blood disorder treating agents include antiplatelets (e.g., aspirin, clopidogrel, prasugrel, ticagrelor), angiotensin-converting enzyme inhibitors (e.g., benazepril, captpril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril), beta-blockers (e.g., acebutolol, atenolol, carvedilol, labetalol, metoprolol, nadolol, nebivolol, penbutolol, pindolol, propranolol), anticoagulants (e.g., warfarin, acenocoumarol, phenprocoumon, dabigatran, apixaban, edoxaban, rivaroxaban), clotting drugs (e.g., Factor VIII, advate, tranexamic acid, desmopressin), hydroxyurea (e.g., droxia, hydrea), antibiotics (e.g., penicillin), statins (e.g., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, pitavastatin), vasodilators (e.g., nitric oxide, doxazosin, prazosin, terazosin, clonidine, hydralazine, minoxidil), or any combination thereof.
- The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.
- This example demonstrates the development of small-molecule PRMT5 inhibitors in an embodiment of the invention.
- In order to identify PRMT5 inhibitors, the AlphaLISA technique (PerkinElmer, Waltham, Mass.) was adapted to an assay that could precisely quantify PRMT5 dimethylation of its substrate in a 384-well HTS platform (
FIG. 1 ). The AlphaLISA high-throughput screen comprises incubating a biotinylated substrate (e.g., histone H4), PRMT5, and a methyl donor (e.g., S-adenosyl-1-methionine (SAM)); PRMT5 dimethylates the biotinylated substrate and the dimethylated biotinylated substrate is recognized by Acceptor beads specific for the methylation site. Donor beads comprising a tag (e.g., streptavadin) bind to the biotinylated substrate, and interaction between the Acceptor beads and Donor beads emits a signal (e.g., chemiluminescent signal), which can be detected. The methylation activity of PRMT5 is proportional to the intensity of the signal. - In one embodiment of the method used to identify the compounds disclosed herein, PRMT5 enzyme was purified with anti-Flag-M2 beads (Sigma-Aldrich, St. Louis, Mo.) from 293 cells overexpressing the Flag-PRMT5 protein (Wei et al., Proc Natl Acad Sci USA, 2013; 110: 13516-13521). The enzyme prep was diluted at 1:10 in assay buffer (30 mM Tris, pH 8.0, 1 mM DTT, 0.01% BSA, 0.01% Tween-20) before use. 100 μM S-adenosylmethionine (SAM) (New England Biolabs, Ipswich, Mass.) was used as the methyl group donor and 30 nM unmethylated histone H4R3 (Anaspec, Thornleigh, Australia) was used as a substrate. For screening, 250 nL of 1 mM library compounds was added to each well with a final compound concentration at 12.5 μM in 1.25% of dimethylsulfoxide (DMSO). All these components were incubated at RT for 1 h. Acceptor beads and donor beads were diluted 1:50 fold in 1× Epigenetics buffer (PerkinElmer, Waltham, Mass.) before use. Acceptor beads were then added at a final concentration of 20 μg/ml to the reaction mixture and the plate was incubated at room temperature (RT) for 1 hour. Donor beads were added at a final concentration of 20 μg/ml, and the plate was incubated at RT for 30 min. The reaction was run in 384 well plates. The plates were read using an ENVISION™ Reader (PerkinElmer, Waltham, Mass.).
- A library of 10,000 small molecules was screened, and several potential compounds were identified to significantly inhibit PRMT5 methylation activity. The PRMT5 inhibitory activity of the compounds from the screen was confirmed using both AlphaLISA and an MTT [(3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide)] assay (PerkinElmer, Waltham, Mass.). For the MTT assay, cells were seeded at 90% confluence in 96-well plates and titrated with different dosages of compound (IIa) for 4 days. Media was then removed and 100 μl of MTT (Sigma-Aldrich, St. Louis, Mo.) was added per well. Cells were incubated for 2 hours at 37° C. before adding 100 μl of DMSO to each well and quantified with the SYNERGY™ H1 Multi-Mode Reader (BioTek Instruments Inc., Winooski, Vt.).
- Amongst the hits, the leading compounds were a compound of formula (II), specifically compound (IIa), a compound of formula (III), specifically compound (IIIa), and a compound of formula (IV), specifically compound (Iva). The IC50 of compound (IIa) was 7.5 μM, the IC50 of compound (IIIa) was ˜1.5 μM, and the IC50 of compound (IVa) was 16.5 μM, as determined by the AlphaLISA (PerkinElmer, Waltham, Mass.) approach in vitro (
FIGS. 2A-2C ). To determine whether compound (IIa) reduced p65 methylation of NF-κB, Flag-p65 expressing cells were treated with 20 μM compound (IIa) for 24 hours, Flag-p65 was then pulled down with anti-Flag-M2 beads and analyzed with Western blot by probing with anti-dimethylated arginine (FIG. 2B ). Compared to the untreated control, treatment with compound (IIa) significantly inhibited PRMT5-mediated p65 methylation. Additionally, compound (IIa) did not inhibit or had at least a 10-fold higher IC50 against other protein arginine methyltransferase family members when analyzed using the HotSpot radioisotope-based platform (Reaction Biology Corp, Malvern, Pa.) (Horiuchi et al., Assay Drug Dev. Technol., 2013; 11: 227-236). - These results indicate that a compound of formula (II), a compound of formula (III), and a compound of formula (IV) can selectively inhibit the activity of PRMT5.
- This example describes the lead optimization of compound (IIa) to identify small-molecule PRMT5 inhibitors with increased PRMT5 inhibitory activity compared to compound (IIa).
- In order to identify small-molecule PRMT5 inhibitors with increased efficacy compared to compound (IIa), lead optimization of compound (IIa) was performed. Briefly, the pyrozolo-pyrimidine core was maintained and peripheral groups were either added or modified. Compounds were tested to identify PRMT5 inhibitors and their corresponding IC50 values using an MTT assay. For the MTT assay cells (HT-29 or PANC1) were seeded at 90% confluence in 96-well plates and titrated with different dosages of compound (IIa) for 4 days. Media was then removed and 100 μl of MTT (Sigma-Aldrich) was added per well. Cells were incubated for 2 hours at 37° C. before adding 100 μl of DMSO to each well and quantified with the Synergy H1 Multi-Mode Reader (BioTek Instruments Inc., Winooski, Vt.).
- Amongst the compounds, the IC50 of compound (Ia) was 2 μM in HT-29 and PANC1 cells, the IC50 of compound (If) was 7 μM in HT-29 and 8 μM in PANC1 cells, the IC50 of compound (Ig) was 7 μM in HT-29 and 11 μM in PANC1 cells, and the IC50 of compound (Ib) was 11 μM in PANC1 cells (
FIGS. 3A and 3B ). - These results indicate that compounds of formula (I) can selectively inhibit the activity of PRMT5.
- This example demonstrates that PRMT5 expression is increased in multiple types of cancer.
- The expression of PRMT5 was examined in pancreatic ductal adenocarcinoma cells at multiple stages of disease progression and in multiple colorectal cancer cell lines. Pancreatic control (HPNE) and cancer cell lines (PANC1, MiaPaCa2 and AsPC1) were grown in Dulbecco's Modified Eagle Medium (DMEM) (GE Healthcare, Little Chalfont, UK), supplemented with 1% of penicillin/streptomycin, 10% fetal bovine serum (FBS). Colon control (FHC) and cancer (HT29, HCT116, and DLD1) cell lines were maintained in RPMI 1640 Medium (Roswell Park Memorial Institute Medium) (GE Healthcare, Little Chalfont, UK), containing 1% penicillin/streptomycin and 10% FBS, while FHC cells were cultured under the same condition with further addition of 25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 10 ng/ml cholera toxin, 0.005 mg/ml insulin, 0.005 mg/ml transferring, and 100 ng/ml hydrocortisone. All cell lines were cultured at 37° C. under 5% CO2.
- The expression of PRMT5 in the cell lines was determined by Western blotting using an anti-PRMT5 specific antibody. As shown in
FIGS. 4A and 4C , expression of PRMT5 was markedly increased in each of the cell lines tested as compared to the corresponding control cell lines. - The expression of PRMT5 was also analyzed in tissue microarray samples using immunohistochemistry. Pancreatic and colon cancer tissue microarrays with matched normal adjacent controls were acquired from OriGene Technologies (Rockville, Md.). The tissue microarrays were blocked using protein-blocking solution (Dako Corporation, Carpinteria, Calif.) for 30 min. All subsequent staining steps were performed using the Dako FLEX SYSTEM and an automated immunostainer. Incubations were carried out at room temperature and tris buffered saline containing 0.05
% TWEEN™ 20, pH 7.4 (Dako Corporation, Carpinteria, Calif.) was used for all the washes and diluents. Anti-PRMT5 primary antibody (Abcam, Cambridge, UK) was used to detect PRMT5 localization. Horseradish peroxidase conjugated to a secondary antibody was then used, followed by addition of the chromogen, which formed a brown precipitate at the binding site of secondary antibody. Imaging was done using an Aperio whole slide digital imaging system (Leica Biosystems, Buffalo Grove, Ill.). The system imaged all slides at 20× magnification. - The expression of PRMT5 was significantly higher in various stages of PDAC (
FIG. 4B ), particularly in the metastatic stage, as compared to the normal PDAC adjacent pancreatic tissue. Similarly, PRMT5 had much higher expression in samples ranging from inflammation, poylp, to the metastatic stage of CRC as compared to CRC adjacent normal colon tissue (FIG. 4D ). - Therefore, these results indicate that the expression of PRMT5 is increased compared to controls in multiple cancer cell types.
- This example demonstrates that PRMT5 promotes cell proliferation, anchorage-independent growth, and cell migration is cells with increased PRMT5 expression.
- The effect of PRMT5 on various characteristics of cancer cells, including cell proliferation, anchorage-independent growth, as well as, cell migration was examined. First, stable cell lines were generated, with either PRMT5 overexpression or shRNA knockdown of PRMT5 in PANC1 (PDAC) and HT29 (CRC) cell lines. Western blotting was carried out to verify the stable overexpression or knockdown of PRMT5 in these cell lines. As shown in
FIG. 5A , the stable cell lines showed desired expression level of PRMT5, as expected. Using the above cell models, the effect of PRMT5 on cell growth was determined. As shown inFIGS. 5C and 5D , overexpression of PRMT5 led to a significant increase in the cell growth, while knockdown of PRMT5 showed opposite effect in both PDAC and HT29 derived stable lines, strongly suggesting that PRMT5 is a promoter for cell proliferation. - The ability to form colonies suspended in soft agar is a characteristic of cancer cells. By using the stable cell lines established above, an anchorage-independent assay in soft agar was conducted. 2.5% and 1.25% agar were used to prepare the bottom and top layers of the soft agar, respectively. The bottom agar was added to each well of a 6-well plate. 2×105 cells for each cell line were then added and mixed into top agar solution and layered on top of the bottom layer. The plates were incubated for 10-20 days at 37° C. and 5% CO2. Images were captured using a Canon EOS Rebel T3i Digital SLR camera (Canon, Woodridge, Ill.) and quantification of colony size and number was performed using ImageJ. PRMT5 overexpression led to a significant increase in not only colony size but also colony number, while shPRMT5 knockdown showed the opposite effect in both PANC1 (
FIG. 5D ) and HT29 (FIG. 5E ) cells. This result confirmed that PRMT5 played a critical role in promoting anchorage-independent cell growth in cells with increased PRMT5 expression. - Another important common feature for cancers is the ability for metastasis. Cancer cells often have a stronger migration ability than normal cells, which is critical for tumor invasion and metastases (Shaw, Methods Mol Biol, 2005; 294: 97-105). Boyden chamber assays were conducted to determine the effect of PRMT5 on the invasive nature of cells with increased PRMT5 activity. 8 μm pore size cell culture inserts (Corning Inc., Corning, N.Y.) were placed in a 24 well plate. Each chamber was coated with gelatin on the side facing the lower chamber. 2×105 cells were suspended in serum-starved media in the upper chamber of the well. Corresponding serum rich media was added to the lower chamber. Migrated cells were fixed using 4% formaldehyde followed by crystal violet staining and counting using a microscope at 20× magnification. The images were captured using a Canon EOS Rebel T3i Digital SLR camera (Canon, Woodridge, Ill.). As observed in
FIG. 5F , overexpression of PRMT5 resulted in an increase in the number of cells that have been migrated, whereas shPRMT5 knockdown reduced this ability as compared to the control cells. Similar effects in CRC cell lines, as shown inFIG. 5G , were also observed. These results pointed out the important role that PRMT5 plays in cell migration. - Taken together, these data show that increased expression of PRMT5 can lead to tumor activity.
- This example demonstrates the in vitro and in vivo efficacies of a compound of formula (I).
- The PDAC and CRC cell lines described above were treated with increasing concentrations of compound (Ia) and quantified for cell viability using the MTT assay described above. As shown in
FIGS. 6A and 6B and summarized inFIG. 6C , compound (Ia) had an IC50 of 4.3 μM in PDAC cells (PANC1), and an IC50 of 2.2 μM in CRC cells (HT29). - Experiments were also conducted to determine whether compound (Ia) exhibits tumor inhibition effects in mice xenograft models of cancer with increased PRMT5 activity. NSG (NOD scid gamma) mice were obtained from the In Vivo Therapeutics Core at Indiana University School of Medicine. After acclimation for 7 days, NSG mice (6-8 weeks old) were xenografted with mycoplasma-free PANC1 or HT29 cells subcutaneously (1×107 PANC1 or 3×106 HT29 cells used per mouse in 0.2 ml of a 1:1 mix of phosphate-buffered saline and MATRIGEL™) (BD Biosciences, San Jose, Calif.). Mice were randomized when tumor volumes reached about 100 mm3. Mice were treated with either vehicle control or 20 mg/kg of compound (Ia) (drug stock dissolved in 1:1 CREMOPHOR™:ethanol solution) intraperitoneally 3 times per week. Tumor volumes and body weights were measured twice a week. The study was performed in accordance with the guidelines and standards of the Institutional Animal Care and Use Committee (IACUC). As shown in
FIGS. 7A and 7B , injection of compound (Ia) did not visibly affect the body weight of the implanted mice, however, it led to significant tumor inhibition effect in both PANC1 (FIG. 7C ) and HT29 (FIG. 7D ) xenografted mice, demonstrating the strong anti-tumor efficacy of compound (Ia) against PRMT5 expressing cancers. - This example demonstrates the in vitro and in vivo efficacies of a compound of formula (II).
- The PDAC and CRC cell lines described above were treated with increasing concentrations of compound (IIa) or the commercially available PRMT5 inhibitor EPZ015666
- and quantified for cell viability using the MTT assay described above. As shown in
FIGS. 8A to 8F and summarized inFIG. 8G , compound (IIa) had a range of IC50 at 2-4 μM in PDAC cells (PANC1, MiaPaCa2 and AsPC1), and a range of IC50 at 10-11 μM in CRC cells (HT29, HCT116 and DLD1). A soft agar experiment was also performed to determine the effect of compound (IIa) on colony growth. As indicated inFIG. 8H , treatment with compound (IIa) strongly inhibited colony formation of both PDAC and CRC cells. - The commercially available PRMT5 inhibitor, EPZ015666, was much less effective as compared to compound (IIa), with a range of IC50 at 50-95 μM for PDAC cells, and a range of IC50 at 180-195 μM for CRC cells (
FIGS. 9A-9F ). - Experiments were also conducted to determine whether compound (IIa) exhibits tumor inhibition effects in mice xenograft models of cancer with increased PRMT5 activity. NSG (NOD scid gamma) mice were obtained from the In Vivo Therapeutics Core at Indiana University School of Medicine. After acclimation for 7 days, NSG mice (6-8 weeks old) were xenografted with mycoplasma-free PANC1 or HT29 cells subcutaneously (1×107 PANC1 or 3×106 HT29 cells used per mouse in 0.2 ml of a 1:1 mix of phosphate-buffered saline and MATRIGEL™) (BD Biosciences, San Jose, Calif.). Mice were randomized when tumor volumes reached about 100 mm3. Mice were treated with either vehicle control or 20 mg/kg of compound (IIa) (drug stock dissolved in 1:1 CREMOPHOR™:ethanol solution) intraperitoneally 3 times per week. Tumor volumes and body weights were measured twice a week. The study was performed in accordance with the guidelines and standards of the Institutional Animal Care and Use Committee (IACUC). As shown in
FIGS. 10A and 10B , injection of compound (IIa) did not visibly affect the body weight of the implanted mice, however, it led to significant tumor inhibition effect in both PANC1 (FIG. 10C ) and HT29 (FIG. 10D ) xenografted mice, demonstrating the strong anti-tumor efficacy of compound (IIa) against PRMT5 expressing cancers. - This example demonstrates that a PRMT5 inhibitor of formula (II) inhibits NF-κB activation and its target gene expression in cells with increased expression of PRMT5.
- Previously, it was discovered that PRMT5 activates NF-κB through methylation of its p65 subunit in HEK293 cells (Wei et al., Proc Natl Acad Sci USA, 2013; 110: 13516-13521; Wei et al., Cell Cycle, 2013; 13: 32-41). As shown in
FIGS. 11A and 11B , overexpresion of PRMT5 enhances NF-κB activity, while PRMT5 knockdown causes the opposite effect in both PANC1 (FIG. 11A ) and HT-29 (FIG. 11B ) cells. To determine if compound (IIa) decreases NF-κB activity, cells transfected with a NF-κB luciferase construct were treated with increasing concentrations of compound (IIa) or the control compound EPZ015666. As shown inFIGS. 11C and 11D , treatment with increasing concentrations of compound (IIa) resulted in a corresponding decrease in NF-κB activation in PANC1 (FIG. 11C ) as well as HT29 cells (FIG. 11D ). In great contrast, a much higher concentration of EPZ015666 was required to observe the same effect (FIGS. 11C and 11D ). These results demonstrate the high efficacy of compound (IIa) to decrease the NF-κB activation in PDAC as well as CRC cells. - The effect of overexpression of PRMT5 on downstream targets of NF-κB was also analyzed. As shown in
FIGS. 11E-11H , overexpression of PRMT5 significantly enhanced IL-1β-triggered typical NF-κB target genes expression, TNFα and IL8, while shPRMT5 exhibited the opposite effect, in both PANC1 (FIGS. 11E and 11F ) and HT29 cells (FIGS. 11G-11H ). - Furthermore, experiments were performed to determine if PRMT5 inhibition by compound (IIa) could decrease the expression of NF-κB target genes (e.g., pro-inflammatory cytokines TNFα and IL-8). Briefly, HT29 and PANC1 cells were treated with or without compound (IIa), and target gene expression was analyzed by quantitative PCR. Treatment with compound (IIa) led to a significant decrease in the expression of TNFα and IL8 in both PANC1 (
FIGS. 11I-11J ) and HT29 cells (FIGS. 11K-11L ), thus indicating that compound (IIa) decreased the PRMT5-mediated NF-κB-dependent gene activation. Overall, compound (IIa) showed significant efficacy in targeted reduction of NF-κB activation as well as its downstream gene activation in both PDAC and CRC cells. - Therefore, taken together, these data show that the PRMT5 inhibitors disclosed herein can reduce that activity of NF-κB and subsequently reduce the expression of NF-κB target genes. Additionally, these data demonstrate that compound (IIa) can be used to treat inflammatory and autoimmune diseases via the inhibition of TNF and IL-8.
- This example demonstrates the efficacy of a compound of formula (III) and a compound of formula (IV).
- The PDAC and CRC cell lines described above were treated with increasing concentrations of compound (IIIa) or compound (IVa) and quantified for cell viability using the MTT assay described above. As shown in
FIGS. 12A to 12L and summarized inFIG. 12M , compound (IIIa) had a range of IC50 at 8.5-12.5 μM in PDAC cells (PANC1, MiaPaCa2 and AsPC1), and a range of IC50 at 5-11 μM in CRC cells (HT29, HCT116 and DLD1), and compound (IVa) had a range of IC50 at 22-51 μM in PDAC cells (PANC1, MiaPaCa2 and AsPC1), and a range of IC50 at 35-50 μM in CRC cells (HT29, HCT116 and DLD1). - These results demonstrate the strong anti-tumor efficacy of a compound of formula (III) and a compound of formula (IV) against PRMT5 expressing cancers.
- This example demonstrates that PRMT5 activity is increased in neurological and neurodegenerative disorders.
- The expression of PRMT5 was analyzed by Western blot is samples from models of Alzheimer's disease. Briefly, samples were taken from non-transgenic B6 mice (6M) (control), hTau (humanized tau mice) (3M), hTau (6M), htau;Trem2−/− mice (6M), hTau (18M), and APPPS1 amyloid mice. Cells overexpresssing PRMT5 were also used as a control. From these data, APPPS1 mice showed a significant increase in PRMT5 protein expression compared to age-matched B6 control mice (
FIGS. 13A and 13B ). Additionally, PRMT5 expression is increased along the aging of another Alzheimer's disease mouse model-hTau expression model and hTau/Trem2−/− mouse model. - Taken together, these data show that PRMT5 activity is increased in neurological and neurodegenerative disorders, and indicate that inhibition of PRMT5 with a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof can be an effective treatment.
- This example demonstrates that a compound of formula (II) can be used to treat a neurological disorder.
- Methamphetamine induces inflammation and activation of microglia through NFκB. Increased NFκB promotes inflammation and excitotoxicity are associated with neuronal damage and decrease in neurotransmitter (NT) levels of dopamine and serotonin. Thus inhibition of NF-κB via compound (IIa) mediated inhibition of its activator, PRMT5 could reduce neurotoxicity observed during post-meth administration and restore NT levels. This data suggests that compound (IIa) may be used to treat methamphetamine abuse.
- Rats were given methamphetamine treatment 7.5 mg/kg, 4 injections spaced out at 2 hours each. Then, 4 injections of 1 mg/kg of compound (IIa) or vehicle control were given at 12 hours, 24 hours, 36 hours, and 48 hours after the last methamphetamine injection. Rats were sacrificed 24 hours after the last injection and neurotransmitter levels were quantified in the striatum using high performance liquid chromatography (HPLC). In the group administered the compound of formula (II), an increase in the levels of NT levels were observed in the striatum region of the rats, thereby suggesting a neuroprotective effect (
FIGS. 14A and 14B ). - These data show that treatment with a compound of formula (II) can be used for the treatment of neurological disorders. Moreover, these data indicate that compounds of formula (I), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof may be effective for the treatment of neurological disorders.
- This example demonstrates that PRMT5 is highly expressed in the heart.
- The expression level of PRMT5 was analyzed in multiple tissues using the TiGER database. The expression profile PRMT5 in humans shows a significant expression of PRMT5 in heart tissue (
FIG. 15 ). - These data indicate that inhibition of PRMT5 with a compound of formula (I), formula (II), formula (III), or formula (IV), or a pharmaceutically acceptable salt thereof may be an effective treatment for cardiovascular disease.
- All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
- The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
- Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims (19)
1. A compound of formula (II):
wherein
R5 is halo, aryl, substituted aryl, heterocycloalkyl, or heteroaryl;
R6 is C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, C1-C8 alkoxy, C3-C6 cycloalkyloxy, aryloxy, halo, C1-C8 haloalkoxy, C1-C8 haloalkyl, haloaryl, haloaryloxy, —CN, —NO2, —(CH2)nC(O)R9, —(CH2)nCO2R9, —(CH2)nC(O)NR9R10, —(CH2)nNR9C(O)R10, —(CH2)nNR9R10, —NR11(CH2)nNR9R10; or
two R6 moieties and the phenyl group to which they are attached form a naphthyl group that is optionally substituted;
R7 is hydroxy, C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, C1-C8 alkoxy, C3-C6 cycloalkyloxy, heterocycloalkyl, aryl, arylalkyl, heteroaryl, aryloxy, halo, C1-C8 haloalkyl, C1-C8 haloalkoxy, haloaryl, haloaryloxy, —CN, —NO2, —C(O)R9, —CO2R9, —C(O)NR9R10, —NR9C(O)R10, —(CH2)nNR9R10, —(CH2)nSO2NR9R10, —(CH2)nSO2R9, aryl; or
two R7 moieties and the phenyl group to which they are attached form a naphthyl group that is optionally substituted;
R8 is H, hydroxy, C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C1-C8 haloalkyl, —CN, —NO2, —(CH2)nNR9R10, heterocycloalkyl, aryl, or heteroaryl;
X is —(CH2)oCR9R10—, —CR9R10(CH2)o—, —(CH2)oNR9—, —NR9(CH2)o—, —(CH2)oO—, or —O(CH2)o—;
R9, R10, and R11 are independently selected from the group consisting of H and C1-C8 alkyl;
m, n, and o are each an integer independently selected from the range of 0-5;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein
R5 is halo, aryl, substituted aryl, heterocycloalkyl, or heteroaryl;
R6 is C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, C1-C8 alkoxy, C3-C6 cycloalkyloxy, aryloxy, halo, C1-C8 haloalkoxy, C1-C8 haloalkyl, haloaryl, haloaryloxy, —CN, —NO2, —(CH2)nC(O)R9, —(CH2)nCO2R9, —(CH2)nC(O)NR9R10, —(CH2)nNR9C(O)R10, —(CH2)nNR9R10, or —NR11(CH2)nNR9R10;
R7 is hydroxy, C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C3-C6 cycloalkylalkyl, C1-C8 alkoxy, C3-C6 cycloalkyloxy, aryloxy, halo, C1-C8 haloalkyl, C1-C8 haloalkoxy, haloaryl, haloaryloxy, —CN, —NO2, —C(O)R9, —CO2R9, —C(O)NR9R10, —NR9C(O)R10, —(CH2)nNR9R10, —(CH2)nSO2NR9R10, or —(CH2)nSO2R9;
R8 is H, hydroxy, C1-C8 alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, C1-C8 haloalkyl, —CN, —NO2, —(CH2)nNR9R10, heterocycloalkyl, aryl, or heteroaryl;
X is —(CH2)oCR9R10—, —CR9R10(CH2)o—, —(CH2)oNR9—, —NR9(CH2)o—, —(CH2)oO—, or —O(CH2)o—;
R9, R10, and R11 are independently selected from the group consisting of H and C1-C8 alkyl;
m, n, and o are each an integer independently selected from the range of 0-5.
3. The compound of claim 2 , wherein R6 is —NR11(CH2)oNR9R10.
4. The compound of claim 2 , wherein R7 is C1-C8 alkyl, halo, or C1-C8 haloalkyl.
5. The compound of claim 2 , wherein R8 is H.
6. The compound of claim 2 , wherein X is —(CH2)oNR5— or —NR5(CH2)o—.
7. The compound of claim 1 , wherein m is 1.
8. The compound of claim 6 , wherein o is 1 or 2.
9. The compound of claim 1 , wherein
R5 is piperazinyl, pyrrolyl, pyranyl, piperidyl, morpholinyl, phenyl, substituted phenyl, and pyrrolidinyl;
R6 is —NR11(CH2)nNR9R10;
R7 is H, C1-C8 alkyl, halo, or C1-C8 haloalkyl;
R8 is H;
X is —NR9—, —(CH2)oCR9R10—, —CR9R10(CH2)o—, or —(CH2)oNR9—;
R9, R10, and R11 are independently selected from H or C1-C8 alkyl;
m is 1; and
o is 1 or 2.
10. The compound of claim 9 wherein R5 is a 3,4-di-C1-C8 alkylphenyl, optionally wherein the 3,4-di-C1-C8 alkylphenyl is 3,4-dimethylphenyl.
12. A pharmaceutical composition comprising a compound of claim 1 or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
13. A method of treating a cancer in a subject, comprising administering the pharmaceutical composition of claim 12 or a pharmaceutically acceptable salt thereof to the subject, whereby the cancer is treated.
14. The method of claim 13 , wherein the cancer has
(i) increased activity of protein arginine methyltransferase 5 (PRMT5) compared to a non-cancer cell from the subject; and/or
(ii) the cancer has a constitutive activation of nuclear factor κB (NF-κB); and/or
(iii) the cancer is a gastrointestinal cancer, skin cancer, lung cancer, brain cancer, ovarian cancer, prostate cancer, lymphoma, melanoma, or breast cancer; and wherein the gastrointestinal cancer is optionally selected from the group consisting of pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, pancreatic cancer, and liver cancer.
15. The method of claim 14 , wherein the compound or pharmaceutically acceptable salt thereof is administered in a composition comprising the compound or a salt thereof and a pharmaceutically acceptable carrier.
16. A method of inhibiting the activity of PRMT5 in a cell, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt thereof, to the cell, whereby the activity of PRMT5 is inhibited.
17. The method of claim 16 , wherein
(i) the cell is a cancer cell; and/or
(ii) the cancer cell is optionally selected from a gastrointestinal cancer, skin cancer, lung cancer, brain cancer, ovarian cancer, prostate cancer, lymphoma, melanoma, or breast cancer; and wherein the gastrointestinal cancer is optionally selected from the group consisting of pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, pancreatic cancer, and liver cancer.
18. The method of claim 16 wherein said cell is present in a subject having a disease associated with increased activity of PRMT5, said method comprising administering a pharmaceutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to the subject.
19. The method of claim 18 , wherein the disease associated with increased activity of PRMT5 is a cancer, an autoimmune disease, an inflammatory disease, a metabolic disorder, a neurological disorder, a cardiovascular disorder, or a blood disorder.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/320,381 US20210269431A1 (en) | 2016-10-26 | 2021-05-14 | Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment |
US18/500,786 US20240083894A1 (en) | 2016-10-26 | 2023-11-02 | Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662413341P | 2016-10-26 | 2016-10-26 | |
US201762534969P | 2017-07-20 | 2017-07-20 | |
PCT/US2017/058572 WO2018081451A1 (en) | 2016-10-26 | 2017-10-26 | Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment |
US201916344644A | 2019-04-24 | 2019-04-24 | |
US17/320,381 US20210269431A1 (en) | 2016-10-26 | 2021-05-14 | Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/058572 Continuation WO2018081451A1 (en) | 2016-10-26 | 2017-10-26 | Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment |
US16/344,644 Continuation US11034689B2 (en) | 2016-10-26 | 2017-10-26 | Small molecule protein arginine methyltransferase 5 (PRMT5) inhibitors and methods of treatment |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/500,786 Continuation US20240083894A1 (en) | 2016-10-26 | 2023-11-02 | Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210269431A1 true US20210269431A1 (en) | 2021-09-02 |
Family
ID=62025487
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/344,644 Active US11034689B2 (en) | 2016-10-26 | 2017-10-26 | Small molecule protein arginine methyltransferase 5 (PRMT5) inhibitors and methods of treatment |
US17/320,381 Abandoned US20210269431A1 (en) | 2016-10-26 | 2021-05-14 | Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment |
US18/500,786 Pending US20240083894A1 (en) | 2016-10-26 | 2023-11-02 | Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/344,644 Active US11034689B2 (en) | 2016-10-26 | 2017-10-26 | Small molecule protein arginine methyltransferase 5 (PRMT5) inhibitors and methods of treatment |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/500,786 Pending US20240083894A1 (en) | 2016-10-26 | 2023-11-02 | Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment |
Country Status (4)
Country | Link |
---|---|
US (3) | US11034689B2 (en) |
EP (1) | EP3532051A4 (en) |
CN (1) | CN110325188A (en) |
WO (1) | WO2018081451A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108689960B (en) * | 2018-06-07 | 2022-03-04 | 济南大学 | 5-benzylidene-2-phenyl thiazolone compound and preparation and application thereof |
CN111686113B (en) * | 2019-03-15 | 2022-12-30 | 北京大学 | Sonic Hedgehog inhibitor and application thereof |
WO2020206289A1 (en) * | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
WO2020206299A1 (en) * | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
GB201908885D0 (en) * | 2019-06-20 | 2019-08-07 | Storm Therapeutics Ltd | Therapeutic compounds |
EP4084871A4 (en) * | 2019-12-31 | 2024-01-24 | Univ Indiana Trustees | Repurposing fda-approved drugs as a novel cancer therapeutic avenue through inhibition of prmt5 |
US20230025976A1 (en) * | 2020-01-07 | 2023-01-26 | Pfizer Inc. | PRMT5 Inhibitor for Use In A Method of Treating Psoriasis and Other Autoimmune Conditions |
WO2022002142A1 (en) * | 2020-06-30 | 2022-01-06 | 江苏先声药业有限公司 | Tetrahydroisoquinoline compounds and use thereof |
CN112831521B (en) * | 2021-02-02 | 2022-07-05 | 中国人民解放军军事科学院军事医学研究院 | Construction method and application of dilated cardiomyopathy mouse model |
CN115124534B (en) * | 2021-11-23 | 2023-09-15 | 中山大学 | Non-nucleotide PRMT5 small molecule inhibitor, preparation method and application |
US20230181589A1 (en) * | 2021-12-03 | 2023-06-15 | The Trustees Of Indiana University | Prmt5 inhibitors for ocular therapy |
WO2023125947A1 (en) * | 2021-12-30 | 2023-07-06 | 江苏先声药业有限公司 | Pharmaceutically acceptable salt of tetrahydroisoquinoline compound, and crystal form and use thereof |
CN114366813A (en) * | 2022-01-21 | 2022-04-19 | 中南大学 | Target for treating tumor, application of target and tumor treatment preparation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962915B2 (en) * | 2002-05-20 | 2005-11-08 | Bristol-Myers Squibb Company | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5064947A (en) * | 1989-03-29 | 1991-11-12 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine reseptor compounds |
TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
EP1149583A3 (en) | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
CA2619365A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
GB0522880D0 (en) | 2005-11-09 | 2005-12-21 | Glaxo Group Ltd | Novel compounds |
JP2012503613A (en) * | 2008-09-25 | 2012-02-09 | ラシオファルム ゲーエムベーハー | Compact cinacalc set |
WO2012009258A2 (en) * | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
US20180271891A1 (en) | 2015-03-11 | 2018-09-27 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
-
2017
- 2017-10-26 US US16/344,644 patent/US11034689B2/en active Active
- 2017-10-26 WO PCT/US2017/058572 patent/WO2018081451A1/en unknown
- 2017-10-26 EP EP17863518.1A patent/EP3532051A4/en active Pending
- 2017-10-26 CN CN201780080769.0A patent/CN110325188A/en active Pending
-
2021
- 2021-05-14 US US17/320,381 patent/US20210269431A1/en not_active Abandoned
-
2023
- 2023-11-02 US US18/500,786 patent/US20240083894A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6962915B2 (en) * | 2002-05-20 | 2005-11-08 | Bristol-Myers Squibb Company | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
Non-Patent Citations (2)
Title |
---|
STN search result, Aurora Fine Chemicals, (STN registry number 921472-94-8, February 16, 2007, p. 1). * |
STN search result, Ryan Scientific, Inc. (STN registry number 1005307-86-7, February 24, 2008, p. 1). * |
Also Published As
Publication number | Publication date |
---|---|
EP3532051A4 (en) | 2020-08-12 |
WO2018081451A1 (en) | 2018-05-03 |
EP3532051A1 (en) | 2019-09-04 |
US20200062745A1 (en) | 2020-02-27 |
CN110325188A (en) | 2019-10-11 |
US11034689B2 (en) | 2021-06-15 |
US20240083894A1 (en) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210269431A1 (en) | Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment | |
Liu et al. | Discovery of orally bioavailable chromone derivatives as potent and selective BRD4 inhibitors: scaffold hopping, optimization, and pharmacological evaluation | |
CA2720908C (en) | Molecules inhibiting a metabolic pathway involving the syk protein tyrosine kinase and method for identifying said molecules | |
CN111789956B (en) | Drug therapy, screening technology and kit for inhibiting side effects caused by chemotherapy | |
JP2010539104A (en) | Combination therapy of cancer with selective inhibitors of histone deacetylases HDAC1, HDAC2 and / or HDAC3 and microtubule stabilizers | |
AU2016249567B2 (en) | Cell death inducing agent for cells having BRAF gene mutation, growth suppressing agent for same cells and pharmaceutical composition for therapy of diseases caused by growth defect of same cells | |
US11739078B2 (en) | Methods of inhibiting kinases | |
KR20150095780A (en) | Apoptosis-inducing agent | |
JP2023512040A (en) | Compounds and uses thereof | |
WO2020047487A1 (en) | Methods for treating cancer with rorgamma inhibitors and statins | |
US20130053415A1 (en) | Combination methods for treatment of disease | |
US20110288114A1 (en) | Compositions for the treatment of fibrotic diseases or conditions | |
US11247970B2 (en) | Selective inhibition of gluconeogenic activity | |
EP2857392A1 (en) | Small compound targeting at tacc3 | |
JP2024023269A (en) | Antitumor agent and compounding agent | |
US20140227289A1 (en) | Compounds and methods for treating insulin resistance syndrome | |
JP2018520990A (en) | Combination of anti-FGFR4 antibody and bile acid scavenger | |
KR20190021369A (en) | (Anti-PCSK9) compounds and methods of using them for the treatment and / or prevention of cardiovascular diseases | |
RU2760835C2 (en) | Agent inducing cell death for cells having braf gene mutations, agent suppressing growth of such cells, and pharmaceutical composition for the therapy of diseases caused by growth defect of such cells | |
US7521463B2 (en) | Immunomodulatory compounds | |
US20220241424A1 (en) | Treatment of cancer | |
CN107849033A (en) | For the compound for the illness for treating the mediation of Rac GTP enzymes | |
WO2023276869A1 (en) | Method for predicting prognosis after treatment with angiogenesis inhibitor, and combination therapy for cancer | |
US20210060130A1 (en) | Pharmaceutical compositions and use thereof for relieving anticancer drug resistance and enhancing sensitivity of anticancer drug | |
EP4168014A1 (en) | Oxopiperazine derivatives for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |